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ABSTRACT 
The increased cell numbers, presence of the blastocoel and rapid cell re-organisation 
have required the development of specific survival criteria post warm to effectively 
select the most viable blastocyst for transfer. Pre-freeze blastocyst expansion and post 
warm re-expansion have been shown to contribute significantly to the chances of an 
implantation and subsequent live birth. The aim of this study was to explore factors that 
influence the outcome of blastocyst transfers after vitrification and warming, and 
hopefully improve outcomes by further applying improvements in future cycles. 
Variables from 8 years of vitrified/warmed blastocysts were retrospectively compiled 
and analysed to determine the most significant contributors to outcome. There were 
2466 transfers of either 1 or 2 vitrified/warmed blastocysts resulting in 796 (32.3%) 
clinical pregnancies and 751 (30.5%) live born babies. The patient/cycle specific variables 
of age: ≤38 years (OR: 2.01, 95% CI:1.48-2.73), transfer order: ≤ 2 (OR:1.32, 95% CI:1.10-
1.59) and cycle type: non-HRT (OR: 1.38, 95% CI:1.15-1.66) significantly influenced the 
live birth outcome. Blastocysts vitrified on day 5 of development had significantly 
improved outcomes to day 6 blastocysts (OR: 1.80, 95% CI: 1.37-2.35). A greater degree 
of blastocyst expansion on Day 5 further improved these outcomes (OR: 1.47, 95% 
CI:1.17-1.86). A grade 1 morphology rating significantly improved the outcomes of day 5 
expanded blastocysts (OR: 1.51, 95% CI:1.24-1.85). The composition of the warming 
media and possibly the concentrations of osmotic buffer contributed to the survival of 
warmed blastocysts. Post warming assessment of the blastocyst showed that if the level 
of cell degeneration in the surviving and transferred embryo was less than 5%, this 
significantly influenced the outcome (OR:1.57, 95% CI:1.22-2.03). There was no 
significant difference if a blastocyst with ≥ 95% cell survival commenced re-expansion 
within 30 or 60 minutes after the warm (OR: 1.13, 95% CI:0.87-1.46). This study 
highlights the significance of even a small number of degenerative cells in the warmed 
blastocyst despite early commencement of re-expansion and warrants further 
prospective analysis. 
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1 INTRODUCTION 
1.1 Background to the Study 
A review of 25 population surveys in 2007 showed a global prevalence of infertility to be 
9% of the population (Boivin, Bunting, Collins, & Nygren, 2007) with estimates of 1 in 6 
couples requiring medical intervention to achieve conception during their reproductive 
lifetime. A report from the World Health Organisation published in 2012 concluded that 
prevalence estimates had changed little over the previous two decades (Mascarenhas, 
Flaxman, Boerma, Vanderpoel, & Stevens, 2012). Despite the stable infertility prevalence 
there is increasing use of Assisted Reproductive Technology (ART) to procreate. The 
proportion of Australian births in 2016 that required some form of ART treatment was 
4.4% (Australian Institute of Health and Welfare, 2018).This compared to 1992 when In 
vitro-fertilisation (IVF) treatment accounted for 0.9% of births (Lancaster, Shafir, & 
Huang, 1995). The latest report from the National Perinatal Epidemiology and Statistics 
Unit (NPESU) describes ART as the most common form of treatment for infertility, with 
over 81,000 ART cycles initiated in Australia and New Zealand in 2016 (Fitzgerald, Paul, 
Harris, & Chambers, 2018).  Despite a significant utilisation of IVF technology, the 
summary embryo data from this report reveals that less than 10% of embryos created 
implant into the uterus. This compares to a reproductive efficiency of a fertile couple in 
their mid-20’s of 25% (Wang. et al., 2003). Decreased implantation rates of embryos 
grown in vitro and the use of single embryo transfer (SET) have led to the development 
of strategies to improve the culture environment and selection of embryos prior to 
transfer.  
Development of nutrient gradients in culture media to mimic the passage of the embryo 
through the fallopian tube and into the uterus has allowed extended use of culture 
beyond the cleavage stage to the blastocyst stage of development (Gardner, 1998). This 
has assisted with embryo selection as only 40-50% of fertilised oocytes reach this stage 
of development in-vitro (Schoolcraft et al., 1999a). Differentiation of the blastocoel, 
trophectoderm (TE) and inner cell mass (ICM) as morphological markers on Day 5 and 6 
of culture also enable a more informative assessment of embryo morphology. It is also 
relevant that the physiological processes of the cleavage stage embryo depend on 
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translation of stored maternal rather than embryonic RNA (Telford, Watson, & Schultz, 
1990).  
Cryopreservation of excess embryos after selection for fresh transfer is well established 
as a successful process, with the first pregnancy in the world for the cleavage stage 
achieved in Australia (Trounson & Mohr, 1983). Vitrification has been the 
cryopreservation procedure of choice for excess blastocysts (Kuwayama, Vajta, Kato, & 
Leibo, 2005) and the recovery of the embryo from this procedure introduces further 
assessment criteria of the warmed blastocyst. The proportion of cell degeneration and 
further division is easily calculated in warmed cleavage stage embryos due to the 
relatively low number of cells (2-8) but the increased cell numbers in blastocysts (100-
150) makes it difficult and inaccurate to perform this analysis. During the equilibration 
and vitrification of blastocysts the blastocoel collapses as the TE breaks contact with the 
zona pellucida (ZP). After warming, the blastocoel re-expands in some embryos and not 
in others, usually within a 3-4 hour period (Desai & Goldfarb, 2005) with better 
implantation results when re-expansion has occurred prior to the frozen embryo 
transfer (FET). 
The maximum time required for a blastocyst to commence this re-expansion and 
successfully implant is unknown. Identifying this time point would help ensure 
embryologists provide the best possible embryo for transfer to the patient. The 
endometrium in frozen embryo transfer cycles is synchronised with the age of the 
embryo which for blastocysts is Day 5 or 6 post ovulation and therefore the in vitro time 
available for blastocyst assessment is limited. This is further exacerbated by embryos 
being frozen singularly and assessments made one embryo/warm at a time.  
1.2 Prevalence of infertility and ART trends in Australia 
Despite the prevalence of infertility remaining constant over 2 decades there are some 
important shifts in society that has seen an increasing use of ART (Mascarenhas et al., 
2012).  In 2017 (Figure 1-1) the median maternal age of child birth of 31.3 years 
compares to 29.8 in the year 2000 and 25.4 in 1971 (Australian Bureau of Statistics, 
2018). Women are choosing to bear children later. The latest NPESU report for ART 
cycles in 2016 shows that the highest live delivery rate per embryo transfer for fresh 
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autologous cycles (36.9%) and autologous thaw cycles (33.3%) was for women aged less 
than 30 years.  
Figure 1-1 Median age of parents, Australia-1937 to 2017 
 
This success rate declined with advancing women’s age with a rate of 1.3% for women 
aged over 44 (Fitzgerald et al., 2018). These figures demonstrate that maternal age has a 
significant impact on fertility and the delaying of conception results in an increased 
utilisation of ART. The same report revealed that more than 1 in 4 women using IVF 
technology to attempt a conception in 2016 were aged 40 or older. There were 15,198 
babies born due to ART in Australia and New Zealand in 2016 according to the NPESU. 
Trends in the provision of ART are detailed in section 7 of the NPESU report. There has 
been a shift in the utilisation of extended blastocyst culture rather than shorter term 
cleavage culture prior to embryo selection for transfer and cryopreservation between 
2009 (49.8%) and 2016 (78.4%). This trend is accompanied by an increase in the 
proportion of cycles not proceeding to embryo transfer from 23.4% to 49.0%. This is 
mainly due to an increasing trend in freeze-all cycles to avoid a transfer in a fresh cycle. 
The proportion of blastocyst warm cycles utilising the vitrification technique for 
cryopreservation increased from 33.2% in 2009 to 87.8% in 2016. 
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The number of SET procedures has increased from 69.7% in 2009 to 87.7% in 2016 
resulting in a drop in multiple deliveries from 8.2% to 3.8%. These achievements have 
occurred while improving live birth rates per embryo transfer from 21.2% to 26.2%. 
1.3 Ovarian stimulation 
The first successful birth utilising IVF technology involved retrieving an oocyte from a 
natural menstrual cycle (Steptoe & Edwards, 1978). To increase the probability of 
successful fertilisation, embryo development and implantation it has been necessary to 
induce multiple dominant folliculogenesis in the ovaries to produce supernumerary 
oocytes for insemination (Claman, Domingo, Garner, Leader, & Spence, 1993). There are 
differing drug regimens that have been utilised to produce this follicular response. 
1.3.1 Clomiphene Citrate 
It was discovered during treatment of endometrial hyperplasia and breast cancer with 
the oral anti-oestrogen Clomiphene Citrate (CC) that it also resulted in ovulation 
induction (Kistner & Smith, 1961).  The oral delivery, preservation of the steroid negative 
feedback and low cost made CC an attractive option for ovarian stimulation during early 
applications of IVF technology (Trounson, Leeton, Wood, Webb, & Wood, 1981).  Anti-
oestrogenic effects localised to the uterus, the recruitment of only 1-2 follicles and 
inhibited cervical mucus production are effects of CC that limit the pregnancy rates of 
this therapy (Gelety & Buyalos, 1993).  Various modifications were developed to combat 
these effects including the use of lower doses (Quigley, Maklad, & Wolf, 1983) and 
supplementing with gonadotrophins (Li et al., 2015).  Due to the reliance on a functional 
hypothalamic pituitary ovarian axis to exert its oestrogen receptor effects, CC is not 
suitable for patients with hypo or hypergonadotrophic hypogonadism (Practice 
Committee ASRM, 2013). 
1.3.2 Gonadotrophins 
Gonadotrophic preparations are the most commonly utilised agents for ovarian 
stimulation in IVF (Lunenfeld, 2004).  Follicle Stimulating Hormone (FSH), Luteinising 
Hormone (LH) and human Chorionic Gonadotrophin (hCG) have evolved in purification 
level and source, from human pituitary gonadotrophin (Gemzell, Diczfalusy, & Tillinger, 
1958) and placental cells (Seegar-Jones, Gey, & Ghisletta, 1943) to recombinant FSH 
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(Howles, 1996; Olijve, de Boer, Mulders, & van Wezenbeek, 1996) and hCG 
(International rhCG Study Group, 2001).  The endogenous response to gonadotrophin 
therapy is monitored with the use of peripheral oestradiol measurements and ovarian 
ultrasonography (Speroff & Fritz, 2005).  There are many factors influencing ovarian 
response including age of the patient and the proportion of antral follicles prior to the 
commencement of gonadotrophin (Rutherford et al., 1988). 
1.3.3 Agonist 
A problem occurring in cycles augmented with exogenous gonadotrophins is the 
spontaneous LH surge that can lead to ovulation prior to oocyte collection in 25-30% of 
cases (Hillier, Afnan, Margara, & Winston, 1985).  The development and application of 
gonadotrophin releasing hormone (GnRH) agonists allowed physicians to flood the GnRH 
receptors in the pituitary with an initial activation followed by desensitization effect, 
thereby suppressing endogenous gonadotrophin release hence preventing premature 
ovulation (Conn & Crowley, 1994).  An added benefit to this pituitary suppression was 
the ability to schedule oocyte retrievals rather than accessing facilities on an emergency 
basis (Rogers et al., 1986). 
1.3.4 Antagonist 
GnRH antagonist analogues act by binding to pituitary receptors excluding endogenous 
GnRH and suppressing pituitary gonadotrophic production with immediate effect and 
recovery.  The rapid effect without a stimulation phase of gonadotrophins allows short 
term suppression of the endogenous LH surge and hence prevention of premature 
ovulation during ovarian stimulation for IVF (Olivennes et al., 1994).  Other advantages 
of GnRH antagonist use in IVF treatment include: reduced costs; shorter duration of 
treatment; less patient discomfort and less gonadotrophins required to produce the 
oocytes (Al-Inany & Aboulghar, 2002; Fauser & Devroey, 2005). 
1.3.5 Mild Stimulation 
The use of gonadotrophins with GnRH analogues has enabled ovarian stimulation 
protocols to produce multiple oocytes for use in IVF but there are also significant side 
effects (Macklon, Stouffer, Giudice, & Fauser, 2006).  High cost of medications, patient 
discomfort from injections, inconvenience due to monitoring strategies and elevated 
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risks associated with ovarian hyperstimulation syndrome (OHSS) are some of the issues 
associated with ovarian stimulation.  To address these sequelae and make stimulation 
regimes more patient friendly, milder strategies have been developed to produce a 
reduced number of oocytes (Verberg et al., 2009). 
1.4 Endometrial Preparation 
Embryo(s) developed in vitro are transferred into a receptive uterus during the 
proliferative/ secretory phase of the endometrium. This can be in the same cycle the 
oocytes were retrieved from or in a subsequent monitored cycle specifically designed for 
the transfer of a frozen/warmed embryo. 
1.4.1 Fresh embryo transfer cycles 
A significant contributor to the failure of early IVF attempts was the method used to 
extend the shortened luteal phase in cycles stimulated with gonadotrophins (Edwards, 
1973). Eventually problems associated with the luteal phase were bypassed in fresh 
embryo transfers by retrieving an oocyte in a natural menstrual cycle and utilising a 
natural luteal phase to nurture the embryo (Edwards, Steptoe, & Purdy, 1980). 
Cancellation and success rates per cycle start however were reduced when compared to 
cycles utilising ovarian stimulation with gonadotrophins (Fahy, Cahill, Wardle, & Hull, 
1995). The use of ovarian stimulation regimes in assisted reproduction and in particular 
GnRH agonists disrupts the activity of the corpus luteum and endometrial preparation 
for implantation (Smitz et al., 1988). Luteal supplementation has been shown to improve 
endometrial quality and subsequent rates of embryo implantation (Soliman, Daya, 
Collins, & Hughes, 1994). 
1.4.2 Frozen embryo transfer cycles 
The use of ovarian hyperstimulation and the production of multiple oocytes and 
subsequent embryos resulted in supernumerary embryos after completion of the fresh 
embryo transfer (Van den Abbeel et al., 1988). Cryopreservation at various stages of 
embryo development has been successful in rescuing these extra embryos (Troup et al., 
1991). Cycles utilising embryos previously cryopreserved require synchronisation of the 
endometrium with the developmental stage of the embryo (Devroey & Pados, 1998). 
Patients with regular cycles and an endometrium receptive to implantation may have a 
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natural cycle monitored to target ovulation (Sathanandan et al., 1991). Patients with 
irregular cycles can be administered hormone replacement therapy (Pattinson, Greene, 
Fleetham, & Anderson-Sykes, 1992) or mild stimulation by gonadotrophins to produce a 
receptive endometrium (Lornage et al., 1990). The successful use of the frozen embryo 
transfer cycle has led to some freeze all strategies where no fresh embryo transfer is 
performed so as to not reduce the chance of embryo implantation by transferring into 
an endometrium compromised by excessive doses of gonadotrophins (Shapiro et al., 
2011). 
1.5 Collection of oocytes and fertilisation 
1.5.1 Oocyte Collection 
After exogenous ovarian stimulation by gonadotrophins with some form of pituitary 
desensitisation (GnRH antagonist/agonist) the ovaries hopefully produce supernumerary 
follicles. Follicular development criteria are calculated in individual clinics according to 
their stimulation regimes but in general when 2-3 follicles ≥17mm are observed with 
ultrasound monitoring after 7-12 days of stimulation, ovulation is triggered by the 
administration of hCG (Tan et al., 1992).  The timing of the egg collection procedure 
subsequent to the hCG trigger can vary between 35-40 hours (Templeton et al., 1986).  
Human oocytes were originally collected using a laparoscopic technique utilised at the 
time for various gynaecological surgeries (Lopata et al., 1974; Steptoe & Edwards, 1970).  
Due to the general anaesthesia required, difficult access due to obstructive pelvic 
adhesions and long recovery times, an alternative approach using an abdominal 
transducer was developed (Lenz, Lauritsen, & Kjellow, 1981).  This procedure soon 
evolved after the development of vaginal transducers to a technique that was quicker 
and less painful requiring shorter recovery times and able to be performed as a day 
procedure (Wikland, Enk, & Hamberger, 1985).  There are however still clinical cases 
that require approaching the ovary trans abdominally (Yovich, Matson, & Yovich, 1989).  
Transvaginal oocyte aspiration (TVOA) requires a 16-17-gauge needle, 30-35 cm in 
length threaded through a guide attached to a transducer that is introduced into the 
vaginal canal.  Negative pressure (100-200 mm Hg) applied using a vacuum pump 
controlled by a foot pedal aspirates the contents of follicles 10mm or greater 
(Blackledge et al., 1986).  The contents of the follicle are then examined using a stereo 
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dissecting microscope and oocyte cumulus complexes (OCC) identified, rinsed in culture 
media and placed in culture at 37 degrees Celsius utilising a physiological bicarbonate pH 
buffering system to maintain the pH at 7.2-7.3.  
1.5.2 Sperm preparation 
Seminal fluid contains 90% secretions from the accessory glands in addition to Sertoli 
cell secretions and spermatozoa from the testes (Kierszenbaum & Tres, 2012). Alkaline 
bases present in these substances provide the spermatozoa with protection from acidic 
denaturation in the vagina (Mann, 1964). The inhibitory effects of seminal fluid also 
prevent sperm from prematurely becoming acrosomally responsive (Cross, 1996). Due 
to these factors sperm must separate from seminal fluid to achieve capacitation and 
subsequent fertilisation (Austin, 1952). This separation is achieved prior to IVF often by 
either using a swim up procedure, density gradient centrifugation or a combination of 
both (Carrell et al., 1998).  
1.5.3 Insemination 
Insemination methods are usually confined to either conventional IVF where a number 
of sperm are placed around the OCC for a period of time, or intracytoplasmic sperm 
injection (ICSI) where individual sperm are isolated and injected into a metaphase II 
oocyte that has been denuded of its cumulus (Palermo, Joris, Devroey, & Van 
Steirteghem, 1992). 
1.5.3.1 IVF 
Currently in most IVF programmes the IVF fertilisation process remains blinded to the 
embryologist due to the presence of the corona radiata that surrounds the secondary 
oocyte. Oocytes retrieved 35-40 hrs after a trigger injection are briefly rinsed in culture 
media and placed in a dish containing media before washed sperm is added. 
Insemination times are usually co-ordinated to enable an embryologist to be available 
18-20 hours later to perform a fertilisation check prior to syngamy. An abbreviated co-
incubation time is practiced in some centres and a systematic review and meta-analysis 
of studies on abbreviated insemination times has shown that as little as one hour’s 
exposure of oocytes to sperm can improve clinical pregnancy rates without 
compromising fertilisation rates (Zhang et al., 2013). Co-incubation times even as short 
as 30 seconds have been shown to reduce polyspermy rates from 7.2% down to 2.8% 
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without compromising fertilisation, embryo development and pregnancy rates (Bungum, 
Bungum, & Humaidan, 2006).  The removal of cumulus cells after the abbreviated co-
incubation period (3-6 hr post insemination) has been performed successfully in some 
centres (Guo et al., 2016; Jin et al., 2014; Xiong et al., 2011; Xue et al., 2013). 
1.5.3.2 ICSI  
It is difficult to estimate the proportion of the various types of aetiologies presenting at 
ART units across Australia and New Zealand as it is based on clinical diagnosis that may 
vary between clinicians (Fitzgerald et al., 2018). According to reported data in 2016, 
10.7% of initiated cycles had a male infertility diagnosis alone with 12.2% having both 
male and female causes of sub-fertility (Fitzgerald et al., 2018).  Male infertility is 
defined in the WHO manual (World Health Organization., 2010) as simply one or more 
abnormalities in the semen. The most successful solution to achieving fertilisation with 
reduced sperm parameters in IVF was described in 1992 as ICSI (Palermo et al., 1992). 
ICSI requires the removal of the cumulus oophora soon after egg collection using a brief 
exposure to exogenous hyaluronidase along with mechanical pipetting using various 
gauge pipettes. Mature metaphase II oocytes are injected with viable sperm that have 
been immobilised by rupturing the plasma membrane around the distal portion of the 
flagellum. ICSI requires specialised micromanipulation equipment attached to an 
inverted microscope and performed by an experienced clinical embryologist. Progressive 
motility is not an essential pre-requisite for fertilisation after ICSI and therefore sperm 
can be sourced from both the epididymis and testicular tissue (Devroey et al., 1994; 
Silber, Ord, Balmaceda, Patrizio, & Asch, 1990) . To aid in the manipulation of sperm 
prior to and during the ICSI process, a high molecular weight polymer, 
polyvinylpyrrolidone (PVP) or a more natural component of the extra-cellular matrix, 
Hyaluronic acid is used (Liu, Feenan, Chapple, Roberts, & Matson, 2017). 
1.5.4 Fertilisation 
Fertilisation after conventional IVF insemination does not require the sperm to travel 
through the various regions of the female reproductive tract. In-vivo numbers of sperm 
reaching the cumulus oophorus complex (COC) are thought to be an overestimate of a 
hundred or so with 10-20 reaching the ZP (De Jonge, 2005). The numbers used for 
gamete co-incubation in vitro, especially with poor starting sperm parameters have been 
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reported up to 1.2 million/ml (Trounson, 1994). As sperm enters the egg vestments, 
hyaluronic activity and hyperactive motility enables acrosome intact sperm to proceed 
through the extra cellular matrix and make surface contact with the ZP (Huszar et al., 
2003). Exposure to zona proteins leads to an acrosome reaction assisting passage 
through the ZP into the perivitelline space (PVS) and the sperm plasmalemma 
subsequently fuses with the oolemma of the oocyte (Chen & Sathananthan, 1986).  
Oocyte activation soon follows with repetitive cytoplasmic oscillations, elevation of 
intracellular calcium levels and the migration of cortical granules towards the oolemma 
(Sathananthan et al., 1994). Cortical granules release enzymes that modify zona proteins 
and prevent further sperm entering the PVS (Ducibella, 1996). Meiosis II resumes with 
the extrusion of the second polar body and the sperm head chromatin decondenses. 
Nuclear envelopes form and the male and female pronuclei migrate toward each other 
with microtubules inherited from the sperm centrosome (Schatten, 1994). 
1.6 Embryo culture, zygote to blastocyst 
1.6.1 Culture Media 
Early culture media formulations used for human IVF were based on simple salt 
solutions such as Earls Balanced Salt Solution (EBSS) or more complex recipes such as 
Hams F10 inherited from animal somatic cell culture systems. Tyrodes T6 and Whittens 
WM1 were also inherited from animal ART laboratories (Mahadevan, Fleetham, Church, 
& Taylor, 1986). By the mid 1980’s a medium more imitative of the fallopian tube 
environment named human tubal fluid medium was formulated (Quinn, Kerin, & 
Warnes, 1985). Some 10 years later media formulations were altered according to 
different metabolic requirements of the human embryo from zygote to blastocyst 
(Leese, 1995). The energy substrate glucose was found to be at a lower concentration 
mid-cycle when compared to the follicular or luteal phases (Gardner, Lane, Calderon, & 
Leeton, 1996). This has also been augmented with improved embryo quality when 
glucose is removed from culture media between the pronuclear (Day 1) and cleavage 
stages (Day 2-3) (Coates, Rutherford, Hunter, & Leese, 1999). It was also demonstrated 
that only a simple set of non-essential amino acids were required during Day 1-3 of 
culture (Lane & Gardner, 1997) and that possibly they could act as modulators of 
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intracellular pH (Bavister, 1993). Later stages of development benefit by the inclusion of 
the essential amino acids (Gardner et al., 1998).  
All embryo culture requires a buffering system to maintain a stable physiological pH. It 
has been shown that ionic exchange mechanisms within human embryos can maintain a 
pH between 7.0 and 7.3 over significant changes in external pH (Dale, Menezo, Cohen, 
DiMatteo, & Wilding, 1998). To avoid stress on these mechanisms the best strategy is to 
keep culture pH in a similar range. Commonly used buffers in ART include NaHCO3 and 
N-2-hydroxyethylpiperazine-N’-2ethansulfonic acid (HEPES). The former requires gassing 
with CO2 while the latter is used when handling gametes and embryos in ambient air. 
The use of NaHCO3 as a non-toxic and physiological buffer also provides nutrient to the 
culture environment and allows manipulation of the pH through the adjustment of the 
concentration of the buffer or the CO2 percentage (Carney & Bavister, 1987). The 
recommendation for human embryos based on the Henderson-Hasselbach equation in a 
culture with 25mM NaHCO3 at sea level is to provide 6% CO2 at 37°C. Reduced oxygen 
tension from atmospheric (20%) to 5% in the gas provided to human embryos in vitro 
has been shown to benefit growth (Catt & Henman, 2000; Dumoulin et al., 1999). 
The majority of embryo culture is performed with some form of macromolecule 
supplementation in the media. Fertilisation through to cleavage and pregnancy is 
possible in protein-free media but consistent performance is improved with 
supplementation (Caro & Trounson, 1986). Whole serum has been used as a protein 
source in culture media but the presence of unknown elements and patient to patient 
variation can affect the quality of embryo culture (Gardner, 1994). Today the most 
commonly used protein ingredient is human serum albumin that was shown to improve 
results when compared to whole serum (Staessen et al., 1990). Due to the biological 
source of these supplements, the risk of transmitting disease and unidentified protein 
components there has been a focus on the development of recombinant and alternative 
macromolecule protein substitutes (Dyrlund et al., 2014). These have already been 
shown to maintain embryo quality and success rates when compared to HSA (Bungum, 
Humaidan, & Bungum, 2002) but the cost of regular use in IVF culture media has 
prevented significant uptake. Other macromolecule substitutes have also been explored 
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including polyvinyl alcohol (PVA), dextran and hyaluronan (Gardner, Rodriegez-Martinez, 
& Lane, 1999; Pool & Martin, 1994). 
Cytokines and growth factors present in the female reproductive tract play a 
multifunctional role in supporting blastocyst development, implantation and ongoing 
foetal health (Kane, Morgan, & Coonan, 1997). One of these cytokines, Granulocyte-
macrophage colony stimulating factor (GM-CSF) has been identified and shown through 
knock out mouse studies to be a significant contributor to ICM size, birth weight and 
subsequent mortality (Robertson, Roberts, Farr, Dunn, & Seamark, 1999). An increase in 
proportion of blastocyst development and subsequent cell number was shown when 
supernumerary human embryos were cultured in medium supplemented with 
recombinant GM-CSF (Sjoblom, Wikland, & Robertson, 1999). A randomised multi-
centre trial found addition of GM-CSF to culture media increased the survival of 
transferred human embryos to live birth and may be beneficial for women with previous 
miscarriage (Ziebe et al., 2013). 
1.6.2 Oil Overlay 
It is common practice to use oil to overlay culture media to avoid rapid changes in 
osmolality, temperature and pH (Brinster, 1963). Media that can be expensive when 
obtained ready made through a commercial source can be used in smaller volumes with 
oil overlay due to the protection from evaporation. The oil also provides a physical 
barrier to airborne particulate matter. Mineral oil is a product of fractional distillation of 
crude petroleum. Further refinement to remove unsaturated hydrocarbons produces 
paraffin oil that is less likely to oxidise and be less reactive. Peroxidation of mineral oil 
leads to the formation of hydroperoxide that can combine with hydrogen to produce 
free radicals that can alter the function of the lipid component of the embryo plasma 
membrane (Otsuki, Nagai, & Chiba, 2007). The degree of peroxidation is dependent on 
exposure to heat, UV light, extended storage, lot number and manufacturer (Otsuki, 
Nagai, & Chiba, 2009). Manufacturers need to ensure these elements are controlled 
during production and distribution to IVF clinics.   
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1.6.3 Incubators 
One of the most important elements in an ART laboratory is the incubation system. This 
is where the oocytes/embryos are cultured for an extended pre-implantation period 
from day 0 when oocytes are collected through to Day 3-6 when embryos are removed, 
transferred to the patient or cryopreserved. There have been novel approaches to 
design a system that nurtures the growing embryo to a standard close to the female 
reproductive tract. These include a submarine incubation system where a pre-gassed 
sealed bag containing the embryos are placed under water in a water bath (Vajta et al., 
2004) and intravaginal culture where embryos are encapsulated and inserted into the 
vagina of the patient for incubation (Ranoux et al., 1988). These approaches have not 
been widely adopted due to inherent technical difficulties in achieving culture 
consistency. Traditionally large, often water jacketed incubators (150-200 litres) with 
CO2, temperature and humidity control were used for human embryo culture. These 
incubators were gassed from a 100% CO2 cylinder and an internal solenoid in the 
incubator-controlled gas injection to maintain a 5% CO2 level with the balance in 
ambient air. These incubators struggled to maintain constant conditions due to the 
repetitive opening required in a busy IVF unit and the smaller volumes used when 
compared to somatic cell culture. Humidity levels especially would struggle to remain 
high during these periods leading to inaccurate CO2 readings as older thermal 
conductivity sensors (TC) required stable humidity and temperature conditions to work 
correctly. Reducing the volume of these units (<50 litres) allowed for quicker recovery 
times and improved blastocyst development (Avery & Greve, 1992). Reducing the 
incubation space even further to less than 0.5 litres in bench top incubators improved 
temperature recovery times from 20 minutes to just 5 minutes (Cooke, Tyler, & Driscoll, 
2002). The smaller volume incubation chambers can have a constant feed of pre-mixed 
gas that enables a cost-effective method of supplying 6% CO2 with reduced oxygen (5%) 
and the balance in N2. Bench top incubators also have customised grooved culture plates 
that allow direct transfer of heat to the culture ware rather than relying on convection in 
a larger box incubator (Fujiwara et al., 2007). Smaller bench top incubators are now 
produced with the additional tool of time-lapse imaging integrated into the instrument 
that has the additional benefit of reduced embryo handling (Cruz et al., 2011). 
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1.6.4 Laboratory Air 
Gametes and embryos are vulnerable to the presence of volatile organic compounds 
(VOC) and chemical air contaminants (CAC) in the immediate environment. The air 
within an IVF laboratory may have elevated proportions of these compounds despite the 
use of high efficiency particulate air filters (HEPA) installed (Cohen, Gilligan, Esposito, 
Schimmel, & Dale, 1997). Full elimination of these contaminants is very difficult in IVF 
laboratories inheriting the workspace used previously for different purposes, but specific 
design-built IVF laboratories require an extensive air management system. This system 
should not only provide HEPA filtration but also reasonable protection from VOC by 
using rapid air exchange and carbon/potassium permanganate filtering. Contaminants 
can also come from within the workspace from new equipment, disposable tissue 
culture ware, compressed gas, sterilising agents and people traffic (Hall, Gilligan, 
Schimmel, Cecchi, & Cohen, 1998). These laboratory items require significant off gassing 
time and personal cosmetics and perfumes should be avoided in the IVF laboratory. The 
effect of VOC on embryo growth is not always obvious and can be realised through poor 
embryo quality and implantation rates (Boone, Johnson, Locke, Crane, & Price, 1999). 
1.6.5 Culture platforms 
There has been extensive research into the chemical requirements of human embryos in 
culture with various culture media formulations being proposed. It is important also to 
consider the physical environment surrounding the developing embryo. The in vivo 
embryo travels constantly through the fallopian tube and is therefore exposed to 
microvilli contact and movement. These factors contrast significantly to culture 
platforms used in vitro (Swain & Smith, 2011). Inert culture dishes made of a plastic 
polymer are in common use in IVF laboratories. The configuration of the culture is varied 
with isolated culture (Rijnders & Jansen, 1999), isolated but shared media (Vajta et al., 
2008), or group culture (Moessner & Dodson, 1995). Various volumes and 
oocyte/embryo densities are used to take advantage of autocrine/paracrine effects 
(Katz-Jaffe, Schoolcraft, & Gardner, 2006). To create a more dynamic culture the 
application of external forces such as shaking (Isachenko et al., 2006), tilting (Matsuura 
et al., 2010), vibrating (Isachenko et al., 2011) and fluid flow (Heo et al., 2010) have been 
used to mimic the dynamic environment of the fallopian tube. These physical forces can 
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refresh the chemical constitution of the immediate environment of the embryo (Smith, 
Takayama, & Swain, 2012). 
1.7 Embryo Selection 
Although there were early attempts at IVF using gonadotrophic ovarian stimulation 
there was still no success at achieving ongoing pregnancies and live births (Talbot et al., 
1976). After the success in the UK of a natural IVF cycle producing the world’s first IVF 
baby, natural cycles hopefully producing one oocyte and one embryo transferred were 
used (Edwards et al., 1980). Success rates were low however and there were significant 
practical limitations due to the requirement to detect the LH surge and perform the egg 
collection procedure at any point in a 24 hr period (Lopata, 1980). Soon after the first 
baby was born there were normal pregnancies reported in controlled cycles using the 
anti-oestrogen Clomiphene (Trounson et al., 1981). The increasing successful use of 
Clomiphene alongside human menopausal gonadotrophin (hMG) and hCG to produce 
multiple oocytes and embryos ultimately resulted in the transfer of more than one 
embryo in a fresh IVF cycle (Edwards, Lobo, & Bouchard, 1996). The elevated proportion 
of multiple births and the associated perinatal complications ultimately resulted in the 
reduction of the number of embryos transferred (Templeton & Morris, 1998). The latest 
figures in Australia and New Zealand for cycles in 2016 show that 87.7% of embryo 
transfer procedures were of 1 embryo (Fitzgerald et al., 2018). This compares to less 
than 10% in 1993 (Lancaster et al., 1995). The widespread use of SET without a 
reduction in implantation rate has been the result of improved culture conditions and 
embryo selection strategies implemented in the laboratory. 
1.7.1 Morphology 
Appearance and rate of development has been the mainstay of embryo selection since 
ovarian stimulation increased the pool available for utilisation (Cummins et al., 1986). 
This strategy is easy to implement with standard microscopy and embryo handling 
equipment but still requires training, competency and precision of the clinical 
embryologist (Braude, 2013; De los Santos et al., 2016). Depending on the facilities 
available, clinic philosophy and local legislation there is an emphasis on selection and 
transfer at different developmental stages of the embryo. This selection uses various 
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scoring systems based on morphological features of the embryo relative to time 
(Hossain, Phelps, Agarwal, Sanz, & Mahadevan, 2016). 
1.7.1.1 Pronucleate Embryo (Day 1) 
The single cell embryo is dependent on oocyte reserves during the early developmental 
stages and therefore oocyte quality is a significant ingredient in any assessment of the 
pronucleate embryo (Braude, Bolton, & Moore, 1988). Fertilisation is dynamic and 
difficult to assess with static observations, but various methodologies have been 
proposed to select embryos with high implantation potential at this stage of 
development. These methodologies are based on the orientation of the pronuclei 
relative to each other and polar body position (Garello et al., 1999), the number and 
distribution of nucleoli within the pronuclei (Tesarik & Greco, 1999) and the timing of 
pronuclear fading and cytokinesis (Scott, Alvero, Leondires, & Miller, 2000). Grading, 
selection and transfer of pronucleate embryos is rarely used in contemporary IVF 
laboratories with the advent of blastocyst culture (Reh et al., 2010). In some 
circumstances when there is a history of embryo fragmentation early selection and 
transfer may be beneficial (Sermondade et al., 2012)  
1.7.1.2 Early Embryo Cleavage (Day 2-3) 
For much of the past 4 decades of IVF the morphology and rate of division of cleaving 
embryos has been used as a measure of implantation potential (Hossain et al., 2016; 
Stylianou, Critchlow, Brison, & Roberts, 2012).  Common to many different grading 
schemes is the assessment of cell number relative to insemination time, comparative 
blastomere size and the proportion of fragmentation (McKiernan & Bavister, 1994; Van 
Royen et al., 1999). These elements are often combined into a cumulative embryo score 
to choose the embryo most likely to implant (Visser & Fourie, 1993). However the 
various scoring systems can be confusing when trying to compare embryo quality results 
and an international consensus may be able to address this (Alpha Scientists in 
Reproductive Medicine, 2011). The validity of these scoring systems have been 
questioned due to the difficulty of tracing embryo implantation when more than one 
embryo is transferred (Hoover, Baker, Check, Lurie, & O'Shaughnessy, 1995). 
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1.7.1.3 The Blastocyst (Day 5-6) 
All stages of blastocyst development share 3 common morphological features in the TE, 
ICM and blastocoel and they form the basis of the most common grading system for the 
selection of viable blastocysts (Gardner & Schoolcraft, 1999a). The first morphological 
signs of cell differentiation occur when blastocoel formation begins approximately 16-20 
hrs after compaction and 95-103 hrs after insemination (Campbell et al., 2013). It results 
in the first dimensional changes to the originating oocyte as the actions of Na+/K+ ion 
pumps located basolaterally in the forming TE cells create an osmotic gradient (Watson 
& Barcroft, 2001). This gradient leads to a passive movement of fluid into the 
extracellular space within the blastocyst which is then contained by tight junctions 
between TE originally formed during compaction. The blastocoel fluid containment, 
restricting fluid leakage by paracellular routes, ultimately results in expansion of the 
blastocyst (McLaren & Smith, 1977). During the expansion process the PVS disappears 
and the ZP thins from a 10-16 µm thickness (Balaban et al., 2002) to just an outline when 
fully expanded prior to hatching. The embryo increases in diameter from the 110-120 
µm average of the secondary oocyte (Griffin, Emery, Huang, Peterson, & Carrell, 2006; 
Payne, Flaherty, Barry, & Matthews, 1997) to an average 265 µm of the expanded 
blastocyst (Richter, Harris, Daneshmand, & Shapiro, 2001). TE cells are the first 
differentiated cell line of the embryo and grow rapidly in number after the onset of 
cavitation with numbers in excess of 200 in the fully hatched blastocyst (Hardy, 
Handyside, & Winston, 1989). Soon after blastulation has begun it is evident that a 
clump of cells form within the blastocoel at one pole of the blastocyst. These ICM cells 
are pluripotent and range in morphology from a large, highly compacted group of cells 
correlating with an improved implantation potential (Richter et al., 2001) to a small to 
non-existent group of loosely compacted cells. The work of Richter et al (2001) 
emphasised the importance of quantifying blastocyst parameters to determine their 
individual influence on implantation outcome. They determined the ICM as the most 
important morphological element when selecting viable blastocysts. Recent studies have 
challenged this work suggesting more emphasis should be placed on the blastocoel and 
the TE rather than the ICM (Ahlstrom, Westin, Reismer, Wikland, & Hardarson, 2011; 
Ebner et al., 2016; Hill et al., 2013; Thompson, Onwubalili, Brown, Jindal, & McGovern, 
2013). 
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1.7.1.4 Morphokinetics 
Time-lapse imaging systems (TLS) have developed from bespoke setups (Payne et al., 
1997) to ready built time-lapse incubators (Meseguer et al., 2011) enabling many 
embryos from multiple patients to be monitored simultaneously. It is now possible to 
replace static observations with images taken every few minutes in multiple focal planes 
without removing embryos from the incubator and without an embryologist present. 
New phenomena in embryo development can now be observed that previously were not 
captured. These include 2nd polar body extrusion (post ICSI), pronuclear formation and 
fading, cleavage patterns, compaction, cavitation, blastocyst expansion and hatching 
dynamics. A combination of observations at various developmental time points can be 
packaged into algorithms to aid in embryo selection (Liu, Chapple, Feenan, Roberts, & 
Matson, 2015). Software recognition of developmental milestones can also semi-
quantify parameters enabling complex embryo selection algorithms to be applied 
(Conaghan et al., 2013). Despite these advances in technology, in 2014 a Cochrane 
review showed there was little peer reviewed evidence that outcomes are improved 
based on better embryo selection criteria in TLS (Armstrong, Arroll, Cree, Jordan, & 
Farquhar, 2015) and that any improvements could be attributed to incubator design. 
This opinion paper has since been followed with others supporting the hypothesis that 
improved outcomes can be realised by using a combination of TLS and traditional 
morphological assessments compared to traditional methods alone (Adamson et al., 
2016). It is possible that these benefits may only be realised with cleavage stage embryo 
transfers rather than extended culture blastocyst transfers (Goodman, Goldberg, 
Falcone, Austin, & Desai, 2016). Another recent prospective, observational, two-centre 
pilot study with a matched control group showed that TLS selected embryos did not 
have significantly improved outcomes compared to static morphological assessments 
alone (Kieslinger et al., 2016). This study however did show that utilising TLS for embryo 
selection enabled the transfer of equally successful embryos with decreased 
morphological scores. 
1.7.2 Extended Culture 
The first IVF successes from ovarian stimulation were through the selection and transfer 
of cleavage stage embryos (Trounson et al., 1981). These early attempts however 
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utilised Clomiphene Citrate and hCG yielding low oocyte numbers. Super ovulation and 
LH suppression with agonists often result in a greater number of oocytes (Rutherford et 
al., 1988) and more confidence in extending the culture period to the blastocyst stage. 
Despite the greater number of embryos available the blastocyst formation and 
implantation rates were reduced during early attempts at extended culture in clinical 
programmes (Bolton, Wren, & Parsons, 1991). The development of complex stage 
specific culture media improved the outcomes of extended culture leading to greater 
clinical implementation (Gardner, 1998) and the most common form of embryo 
selection in use today (Wang, Kovacs, & Sullivan, 2010).  
1.7.3 Genetic Screening 
Advances in the techniques used for genetic analysis of embryos has enabled increasing 
use of pre-implantation genetic screening (PGS) to ensure the transfer of only euploid 
embryos to the patient (Munné, 2006). If supplemented with extended culture and 
blastocyst biopsy there is evidence that 52% of blastocysts may be euploid compared to 
30% of cleavage stage embryos (Fragouli et al., 2011). The use of high resolution next 
generation sequencing (NGS) has also helped with the identification of levels of 
mosaicism believed to be up to 30% in blastocysts (Grifo et al., 2015).  
1.7.4 Biochemical markers of viability 
There has been much work on the identification of bio-markers of viability for human 
embryos that are non-invasive and better quantify evidence for embryo selection. 
Oocyte respiration analysis has shown a variation of ATP production in unfertilised 
oocytes in an IVF programme and may be a future tool for embryo selection (Obeidat et 
al., 2018). The measurement of proteins in the supernatant of culture media used for 
embryo culture has identified possible indicators of embryo viability (Katz-Jaffe & 
Gardner, 2008; Warner, Lampton, Newmark, & Cohen, 2008).  Amino acid production 
and depletion of embryos as measured in culture media has much potential in the 
selection of viable embryos (Sturmey, Brison, & Leese, 2008). Raman (low frequency) 
and near infrared (NIR) spectrophotometric analysis of the culture medium surrounding 
embryos has enabled the quantification of the secretome (ATP, fatty acids, glucose, 
cholesterol, hormones and other signalling molecules) providing a snapshot of embryo 
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health that has shown some correlation to embryo implantation potential (Nagy, Sakkas, 
& Behr, 2008). 
1.8 Embryo transfer 
Embryo transfer techniques in common use today involve access to the uterus via the 
cervical canal and have changed little since the early pregnancies in IVF (Trounson et al., 
1981). A retrospective study of embryo transfer procedures with difficulty achieving 
passage through the cervical canal has shown poorer outcomes compared to easier 
transfers (Tomás, Martikainen, Tapanainen, Tikkinen, & Tuomivaara, 2002). The addition 
of ultrasound guidance using an abdominal transducer has however improved the 
accuracy and outcome of the procedure especially when access is difficult (Kan et al., 
1999; Sallam & Sadek, 2003). The use of ultrasound guidance has enabled the 
documentation of embryo positioning and a position closer to the fundus has also been 
shown to positively influence outcomes (Wong et al., 2016). Surgical transfer techniques 
have been explored in the past due to perceived problems with this approach, including 
the induction of contractions in the myometrium possibly moving embryos into the 
cervix or upward to the fallopian tubes (Righini et al., 1998). Contamination of the 
uterine environment from microbes present in the cervical mucus and adhering to the 
transfer catheter is also considered a risk (Tan, Bennett, & Parsons, 1990). Surgical 
approaches included gamete intra-fallopian transfer (GIFT), suitable for patients without 
tubal occlusion, where a preparation of sperm and oocytes are introduced abdominally 
via laparoscope to the fallopian tube (Asch, Balmaceda, Ellsworth, & Wong, 1985). If 
sperm parameters were suboptimal then oocytes were fertilised in vitro and transferred 
to the fallopian tube by zygote intra-fallopian transfer (ZIFT), pronuclear stage embryo 
transfer (PROST) or tubal embryo transfer (TET) (Balmaceda et al., 1988; Devroey et al., 
1986; Yovich et al., 1987). The utilisation of tubal transfers has progressively been 
replaced with the earlier cheaper and less invasive cervical procedures due to other 
advances in ART. These include the development of complex culture media enabling 
blastocyst transfers, ICSI and assisted hatching (Ménézo & Janny, 1996). The use of 
media supplementation with adherence compounds such as hyaluronan has been 
shown to offer some benefit to the embryo transfer procedure (Bontekoe, Blake, 
Heineman, Williams, & Johnson, 2010). 
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1.9 Embryo cryopreservation 
1.9.1 Early work with sperm and mouse embryos 
The original challenge in the cryopreservation of living cells was to avoid intracellular ice 
formation and avoid the deleterious effects of increasing extracellular solute 
concentrations due to ice formation (Mazur, 1963; Muldrew, 2008). Non-toxic, low 
molecular weight, water soluble molecules that disrupt hydrogen bonds between water 
are common in animal and plant species that are required to survive sub-zero 
temperatures (Gosden, 2011). The use of 10% dilutions of cryoprotectant agents (CPA) 
glycerol, propylene glycol or ethylene glycol (EG) to achieve this during the slow freezing 
of semen to -79 °C showed good recovery rates (Polge, Smith, & Parkes, 1949). However, 
each cell type has different requirements in cooling rates depending on cell membrane 
permeability and CPA used. The work of Whittingham and colleagues on the successful 
cryopreservation of mouse embryos at various stages laid the foundation for many of 
the slow freezing protocols used today (Whittingham, Leibo, & Mazur, 1972). They 
showed superior results using Dimethyl Sulphoxide (DMSO) with slow rates of freezing 
for mouse embryos rather than the use of glycerol. DMSO (C2H6OS) with a molecular 
weight of 78.13 g/mol has a freezing point of 18.5°C but the freezing point in solution 
(eutectic point) is less than -60°C (Kleinhans & Mazur, 2007). 
1.9.2 Slow freezing trials of Human Embryos 
The use of gonadotrophins for ovarian stimulation often produced more embryos than 
could be transferred to the patient safely in the fresh cycle and this scenario introduced 
embryo cryopreservation as a technique that IVF laboratories were obliged to 
incorporate into their services (Trounson, Wood, & Leeton, 1982).  
1.9.2.1 Pronucleate and Cleavage Stage 
A trial of 1M glycerol vs 1.5M DMSO as a CPA on day 2-3, 4-8 cell embryos demonstrated 
the superiority of DMSO, most likely due to the reduced permeability of glycerol into the 
large blastomeres of the cleavage stage embryo (Trounson & Mohr, 1983). Serial 
dilutions at room temperature were used prior to sealing in a glass ampoule and 
reducing the temperature with liquid nitrogen and a programmable freezer. The 
transfers were scheduled 12 hrs following the warm with a blastomere survival rate of 
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≥50% considered suitable for transfer. The use of propylene glycol, also referred to as 
1,2 propanediol (PROH), was also trialled as a CPA for cleavage stage embryos (Lassalle, 
Testart, & Renard, 1985). PROH was considered a better option than DMSO due to 
reduced toxicity with increasing exposure time (Renard & Babinet, 1984) and reduced 
ice crystal formation on removal from LN2 (Boutron & Kaufmann, 1979). Increasing use 
of PROH showed better survival of embryos during day 1-2 of culture rather than latter 
stages and freezing at the pronucleate stage became a commonly used technique 
(Testart et al., 1986). Supplementation of a non-permeating CPA such as sucrose at 0.1M 
in addition to PROH during freezing was shown to improve embryo survival by assisting 
in cell dehydration, membrane stability and increasing CPA concentration within 
embryonic cells (Mandelbaum et al., 1987). The hypertonic concentration of sucrose 
prevents the rapid rehydration of the embryo which impedes the passage of CPA out 
during warming (Leibo & Mazur, 1978). 
1.9.2.2 Blastocyst Stage 
The use of glycerol as a CPA for blastocysts was successful at producing pregnancies and 
a live birth in a trial including DMSO (Cohen, Simons, Edwards, Fehilly, & Fishel, 1985). A 
subsequent comparison of cryopreservation at the cleavage and blastocyst stages 
concluded that a protocol of fresh transfer of cleavage stage embryos and 
cryopreservation of blastocysts was most efficient in their IVF programme (Fehilly, 
Cohen, Simons, Fishel, & Edwards, 1985). Equilibration of blastocysts in glycerol required 
increasing concentration steps for 10min each at room temperature prior to 
containment in an ampoule and loading into a programmable freezer. Blastocyst 
warming also required time consuming equilibration to remove the CPA. Reflective of 
culture conditions of the time, the blastocyst cryopreservation rate was reduced 
(183/784; 23%). Survival of blastocysts after thawing was based on the re-expansion of 
the blastocoel during a subsequent culture period (2-20 hrs). Cleavage stage embryos 
with ≥50% of blastomeres intact were transferred 2-43 hrs after thawing. The survival 
rate was 66% in blastocysts compared to 35% in cleavage stage embryos. Subsequent to 
this trial the use of PROH and non-permeating cryoprotectants further improved the 
success of slow cooling cleavage stage embryos (Testart et al., 1986). 
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1.9.3 Embryo Vitrification 
Various improvements have been made to slow freezing protocols with the use of 
0.25ml cryostraws that increase the warming rate to 300°C/min rather than large 
cumbersome ampoules (Renard & Babinet, 1984). Adding of the osmotic buffer sucrose 
in freezing and warming solutions and the acceleration of freezing between -35°C and -
80°C also allowed the duration of the procedure to be shortened. However, the major 
improvements have come in the form of vitrification. The term vitrification, as used for 
contemporary embryo cryopreservation, refers to the process in which the entire 
specimen, including intra and extra cellular space forms an amorphous glassy solid 
(Gosden, 2011). Vitrified embryos were used in 83.7% of the 29,820 frozen warmed 
embryo transfer cycles in Australia in 2016. The  live delivery rate per embryo transfer 
was  29.0% in autologous cycles with 82.8% of these transfers being SET (Fitzgerald et 
al., 2018). 
1.9.3.1 Oocytes, Pronucleate and Cleavage Stage Embryos 
As IVF clinics were implementing slow freezing techniques in their laboratories animal 
reproductive biologists were trialling rapid freezing techniques using much higher 
concentrations of solutes (Rall & Fahy, 1985). However, initial attempts at duplicating 
this methodology in human embryos was disappointing (Quinn & Kerin, 1986). In 
addition to the challenges of intracellular ice formation, fracture from extracellular ice 
precipitation and swelling during CPA removal there was the problem of toxicity of the 
elevated CPA concentrations used (Mukaida et al., 1998). The poor results from 
attempts at slow human oocyte cryopreservation when compared to embryo stages, 
despite the use of ICSI and PROH (Porcu et al., 1997; Tucker, Morton, Wright, Sweitzer, 
& Massey, 1998), motivated scientists to trial vitrification as a solution for human 
oocytes (Kuleshova, Gianaroli, Magli, Ferraretti, & Trounson, 1999). This group used 10% 
EG for 40s, 20% for 30s and 40% for 60s all at 37°C to equilibrate oocytes before loading 
into open pulled straws (OPS) (G. Vajta et al., 1998). Sucrose was also added to the 40% 
EG solution at 0.6 mol/l. Straws were then plunged directly into liquid nitrogen (-196°C) 
giving a cooling rate of 20 000°C/min. Warming was directly into decreasing sucrose 
concentrations from 0.4mol/l to 0.125mol/l at 37°C. Variations of this methodology also 
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produced pregnancies after vitrification of pronuclear and cleavage stage embryos (El-
Danasouri & Selman, 2001; Selman & El-Danasouri, 2002). 
1.9.3.2 Blastocysts 
The use of extended culture and vitrification techniques has made frozen embryo 
transfer implantation rates as successful as those of fresh (Roy, Bradley, Bowman, & 
McArthur, 2014). The development of unique vessels to carry the blastocysts through 
the vitrification process with a reduced volume as low as 0.1µl has enabled 
cooling/warming rates in excess of 20 000°C/min and lower concentrations of CPA to be 
used (Arav, Shehu, & Mattioli, 1993; Choi et al., 2000; Kuwayama, 2007; Lane, 
Schoolcraft, & Gardner, 1999; Martino, Songsasen, & Leibo, 1996; Roy, Brandi, et al., 
2014; G. Vajta et al., 1998). A vitrification method utilising a thin polypropylene strip 
0.1mm in depth, 0.4mm wide and 20mm in length protected by a 30mm long sheath has 
proven to produce significantly improved results for the cryopreservation of blastocysts 
(Kuwayama, Vajta, Ieda, & Kato, 2005). Accelerated cooling and warming rates up to 40 
000 °C/min, a reduced volume <0.1µl, versatility, safety and ease of use has made this 
device efficient for oocytes, zygotes, cleavage and blastocyst stages of human embryos 
(Kuwayama, 2007). EG and DMSO have been shown to be easily permeable beyond the 
plasma membrane (Fahy, Levy, & Ali, 1987) and they were used first successfully as an 
equal proportion combination in mice (Ishimori, Takahashi, & Kanagawa, 1992). This 
combination along with an osmotic buffer such as sucrose or trehalose has now become 
ubiquitous amongst IVF centres for the vitrification of human embryos including 
blastocysts (Argyle, Harper, & Davies, 2016).  
1.9.4 Survival 
Survival of embryos after cryopreservation can only be determined at the time of the 
warm. A blastomere survival rate ≥ 50%, e.g. 2/4 cells, is considered sufficient to 
diagnose a cleavage stage embryo as survived and select for transfer. It is important, 
however, to distinguish between those embryos with 100% blastomere survival and 
those with partial survival (Edgar, Bourne, Speirs, & McBain, 2000). Efficacy of 
cryopreservation methods for the blastocyst (survival) can be assessed by normal 
response to osmotic changes (re-expansion) during the dilution process at the time of 
the warm (Kuwayama, Vajta, Ieda, et al., 2005). A unique feature of the blastocyst is the 
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presence of the blastocoel which can present problems in the evacuation of water and 
the influx of cryoprotectant during vitrification. The possibility of ice crystal formation is 
directly proportional to the volume and inversely proportional to the viscosity and 
cooling rate (Liebermann et al., 2002). The artificial reduction of the blastocoel prior to 
vitrification showed some success at increasing the survival rate of expanded blastocysts 
from 30 to 60% (Vanderzwalmen et al., 2002). Some protocols now routinely use 
collapsing prior to vitrification and assisted hatching prior to transfer of warmed 
blastocysts (Desai et al., 2016). The advantage of oocyte, zygote and cleavage stage 
cryopreservation is that survival can be determined by assessing further development 
from 24 hrs through to the blastocyst stage on day 5-6 (Liebermann & Tucker, 2002). 
These embryo stages often have less than 9 cells to assess and survival criteria can be 
based on further cytokinesis of blastomeres. There have been attempts to replicate this 
methodology for blastocysts, but they have many cells, are rapidly re-organising their 
cell structure and are often already hatching and expected implantation is imminent. 
This requires observation over a shorter time-span to assess cell survival, expansion and 
hatching prior to selection for transfer (Yeoman et al., 2001). Blastocyst cryo-survival has 
been defined as cell survival immediately after warming and the absence of dark 
granular cells and areas of degeneration being the essential criteria without reference to 
expansion (Desai et al., 2016). Survival of cells is difficult to assess objectively and 
accurately however unless blastocysts are fixed and stained with nuclear and vitality 
stains (Lopes et al., 2015). There is a greater emphasis on re-expansion of blastocysts 
and cell-reorganisation in some protocols (Ahlström, Westin, Wikland, & Hardarson, 
2013). Zech et al warmed blastocysts 18-22 hrs prior to transfer, assessed under 200x 
magnification immediately after warming and again prior to transfer. If at 24hrs there 
was evidence of a blastocoel and structural integrity of the ICM, the embryo was 
transferred (Zech, Lejeune, Zech, & Vanderzwalmen, 2005). This strategy has also been 
used for day 4 morula stage embryos warmed 48 hrs prior to transfer (Ishimori et al., 
1992). These methods may however require the warming of more than one blastocyst to 
ensure the greatest possibility of the transfer of a viable blastocyst in a synchronised 
cycle. If a blastocyst is deemed not to have survived, there is not enough time to 
perform another warm and assessment prior to transfer (Ahlström et al., 2013). 
Wirleitner et al (2016) defined survival as re-expansion and further development 3 hours 
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after warming. Slow and incomplete re-expansion within 3 hours and poor morphology 
grading relative to pre-freeze morphology was regarded as delayed recovery. There was 
no transfer of a blastocyst when there was no re-expansion after 3 hours and cells 
showed signs of degeneration and lysis (Wirleitner, Schuff, Stecher, Murtinger, & 
Vanderzwalmen, 2016). Shu et al retrospectively compared two groups of warmed 
blastocysts and their resulting implantation rate. They allocated the groups based on 
fast and slow re-expansion but defined these categories by the proportion of re-
expansion at the end of the 2-4 hour period prior to transfer (Shu et al., 2009). They 
found significantly higher rates of implantation (26.7% vs. 11.3%) when the transferred 
blastocyst had a fast re-expanding blastocoel compared to a slow re-expanding 
blastocoel. 
The Alpha (Scientists in Reproductive Medicine) consensus on survival of blastocysts 
after cryopreservation is that ≥75% of cells are intact after warming. Although re-
expansion after 2 hours was considered it was not included due to discrepancies in the 
time available post warming to make such an assessment (Alpha Scientists in 
Reproductive Medicine, 2012). Despite this there are groups using different criteria such 
as ≥50% morphological survival (cells intact) and signs of re-expansion before transfer 
(Van Landuyt et al., 2015).  
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2 SUMMARY and AIMS 
The transfer of blastocysts that have a low implantation potential due to damage 
following vitrification and warming will result in poor pregnancy rates (Ahlström et al., 
2013). This is a waste of resources, gives patients false hope, and results in treatment 
taking longer without any improved outcome. This present study aims to retrospectively 
identify variables from a blastocyst vitrification programme that were significantly 
associated with survival and live birth outcomes. These associations may then be utilised 
to modify existing protocols and better manage patient expectations of a successful 
outcome. This would potentially decrease the number of embryo transfer procedures 
required to achieve a pregnancy.  
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3 MATERIALS and METHODS 
This is a retrospective cohort study of blastocysts that have been vitrified and warmed 
during the period from 2008 to 2015. The primary outcome measure is a live birth from 
those embryos deemed to have survived and subsequently transferred to the patient. A 
comparison is made between different variables that may influence this primary 
outcome including vitrification and warming techniques used over time. 
3.1 Ethics 
All research involving human participants requires adherence to the National Statement 
on Ethical Conduct in Human Research that is a series of guidelines made in accordance 
with the National Health and Medical Research Council Act 1992. Research undertaken 
at Hollywood Fertility Centre required approval from the Hollywood Private Hospital 
Ethics Committee and this was obtained (Appendix 7.1.1). Ethics approval was also 
granted by the Edith Cowan University Research Ethics Committee (Appendix 7.1.2). The 
research method identified for this project is the analysis of retrospective data involving 
human beings. Important issues covered in the ethics application include: 
3.1.1 Consent to the use of Data 
An acknowledgement and agreement was sighted and signed by the gamete providers 
of the embryos involved in this study. This agreement outlined the potential use of data 
collected during treatment for research and quality improvement processes. 
3.1.2 Risk 
As this was a retrospective data analysis, the only identified risk was the disclosure of 
sensitive personal information. This risk was managed by de-identifying data prior to 
analysis and an employer/employee confidentiality agreement as the principal 
researcher is a full-time employee of the IVF unit. 
3.1.3 Benefit 
The negligible risk was outweighed by the benefits associated with the data analysis. 
These include identification of blastocyst survival criteria associated strongly with live 
birth outcomes. These benefits are realised by improved outcomes for patients, more 
efficient use of resources, advancement of knowledge and benefits to society in 
improving the outcomes of ART. 
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3.1.4 Data and Privacy 
The data used in this study was categorised as re-identifiable coded information sourced 
from a database used during the normal course of an IVF cycle and stored on the secure 
servers at Hollywood Fertility Centre. The Hollywood database is a Microsoft SQL Server 
2008 R2 database with security managed via Windows Active Directory accounts and 
groups. The only patient information that leaves the Hollywood Fertility Centre’s 
premises is encrypted with 256-bit encryption solely for offsite disaster recovery 
purposes. 
3.1.5 Translation into Clinical Practice 
Any significant findings from this work will be published and presented at conferences to 
highlight the importance of looking more closely at the changing blastocyst after 
vitrification and warming. These protocols can then be assessed by prospective clinical 
trials and implemented into clinical practice if proved beneficial by improved outcomes. 
3.2 Data retrieval 
The data collection period commenced in February 2008 as the embryo 
cryopreservation systems moved to 100% vitrification at this time. The end date chosen 
was May 2015 due to moving to a different data base making consistent data entry and 
retrieval difficult. 17 fields of data were collected for each blastocyst warmed, 20 for 
each transferred and 25 for each birth outcome (Appendix 7.2). Blastocysts that had 
been biopsied, vitrified, warmed and transferred as known euploid were removed from 
the data set to avoid bias. Data was imported into a Microsoft Excel document that is 
securely stored using Windows Active Directory on the Hollywood Fertility Centre 
Servers. Data was retrieved for 2977 blastocysts that were vitrified and warmed. 
3.3 Data analysis 
Categorical variables were analysed using Pearson’s chi square test or Fisher’s exact test 
with Bonferroni correction for multiple comparisons. Independent t-test or Mann–
Whitney U-test was used for continuous variables depending on the normality of the 
distribution.  Normality was assessed using the Shapiro–Wilk test. Statistical significance 
was defined as P < 0.05 for single comparisons and adjusted lower for multiple 
comparisons (Bonferroni correction). Simple and multiple logistic regression was used to 
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calculate odds ratios. All analyses were performed with the use of SPSS 22 Statistical 
software (IBM, Armonk, New York), vassarstats.net. 
3.4 Risks and limitations 
This study included a retrospective analysis of data with an outcome measure that was 
known at the commencement of the study. Retrospective studies are vulnerable to 
sources of bias and confounding and results should be treated with caution. Most 
evident confounders were controlled for by multivariate analysis, but unknown sources 
could cause residual confounding. The period of the study may include other changes in 
protocols and procedures which may influence the outcome. Only good quality 
blastocysts are considered for cryopreservation, warming and transfer and therefore 
results cannot be generalised for all blastocysts. 
3.5 Patient Population and Setting 
This study was performed in a private specialist medical centre treating patients 
presenting with infertility. The outcomes of blastocysts vitrified and warmed from 2008 
to 2015 were examined. 
3.6 IVF Treatment 
3.6.1 Ovarian Stimulation 
All patients starting stimulation had a BMI <35 kg/m2, P4 < 5.0 nmol/l and FSH ≤ 15 
IU/ml. Ovarian stimulation was initiated by the administration of recombinant follicle 
stimulating hormone (rFSH) injections 125 – 300IU/daily (follitropin-α, Gonal F®, Merck 
Serono Australia or follitropin-β, Puregon®, MSD), beginning day 3 of the menstrual 
cycle. Follicular response was assessed via vaginal ultrasound on days 2, 6 and 11. 
Plasma oestradiol (E2), progesterone (P4) and luteinising hormone (LH) were also 
measured on days 2, 6 and 11. Dosage was altered accordingly depending on ovarian 
response. 
To prevent premature ovulation the GnRH antagonist Orgalutran® (Merck Sharp and 
Dohme, Australia) was administered at 0.25 mg/ daily when the leading follicle diameter 
reached 14 mm. Final follicular maturation (trigger) was achieved by the administration 
of 0.25 mg Ovidrel® (Merck Serono Australia) when at least three follicles had reached a 
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mean diameter of 17mm. Trans-vaginal oocyte aspiration (TVOA) was performed 35-38 
hours after Ovidrel® was administered. 
3.6.2 Blastocyst Culture 
Insemination was performed, 41-44 hours post trigger via conventional IVF or where 
indicated, ICSI. Gamete co-incubation occurred in Sydney IVF Fertilisation Media (COOK® 
Medical, Australia) and fertilisation check occurred 16-18 hours post insemination. 
Zygotes were moved into 20µl droplets of Cleavage Media (COOK® Medical, Australia) 
with no more than 5 per droplet. Embryos were cultured in the MINC incubator (COOK® 
Medical, Australia) in 5% O2, 6% CO2, and 89% N2. Embryonic development was assessed 
on days 3, 5 and 6 of culture, with embryos from day 3 forward being cultured in a 
separate 20µl droplet of Blastocyst Media (BM, COOK® Medical, Australia). Cleavage 
stage division of embryos was examined using a 2-factorial system 68 ± 1-hour post 
insemination. Cell number and degree of cytoplasmic fragmentation was examined for 
each embryo. One hundred and sixteen hours ± 2 hours post insemination (Day 5) 
embryos were graded using a two-component grading system; 1) degree of expansion as 
indicated by the presence of a blastocoel cavity and 2) ICM and TE quality. The assessed 
ICM and TE cells were assigned a numerical grade. Grades 1-2 indicate a discernible to 
distinct ICM and cohesive to lose layer of TE cells. Any embryo with no visible ICM or few 
or uneven layer of TE was not considered suitable for transfer or vitrification on day 5 
and remained in culture for reassessment on day 6. 
3.6.3 Blastocyst Vitrification and Warming 
During the data collection period there were two protocols used for blastocyst 
vitrification utilising different devices, media, equilibration and vitrification techniques. 
3.6.3.1 Hollywood Modified CVM™ Method. 
The CryoLogic Vitrification Method (CVMTM) is a commercially available vitrification kit 
incorporating the use of a FibreplugTM and the solid surface vitrification (SSV) method 
(Appendix 7.3.1). A modified version of this protocol was used incorporating 
equilibration and vitrification solutions from supplier A and warming solutions from 
suppliers A, B and C. (Appendix 7.3.6).  
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3.6.3.1.1 FibreplugTM Vitrification (Detail Appendix 7.3.2) 
Blastocysts were equilibrated singularly for 2 minutes at 37°C in a solution of 8% EG/ 
DMSO containing osmotic buffer while the blastocoel was collapsed using a 200 µm 
pipette. The blastocyst was then moved to a vitrification solution of 16% EG/DMSO for 
30 seconds prior to dispensing onto the FibreplugTM in a 3 µl drop. The FibreplugTM was 
then placed against a stainless-steel vitrification block, pre-equilibrated in liquid nitrogen 
where the drop formed a glass like bead. Once vitrified the FibreplugTM was placed inside 
a pre-cooled sheath and stored in LN2. 
3.6.3.1.2 FibreplugTM Warming (Detail Appendix 7.3.3) 
Fibreplugs were removed from LN2 and plunged into a solution pre-incubated at 37°C 
containing an osmotic buffer (sucrose or trehalose). Once identified, the blastocyst was 
immediately washed free of the vitrification media and moved through a series of 
solutions with decreasing concentrations of osmotic buffer (Appendix 7.3.8)  in 5-minute 
intervals. The blastocyst was then moved to culture in BM prior to assessment for 
survival. 
3.6.3.2 Hollywood Modified Cryotop® Vitrification Method (CT) 
The Cryotop® Vitrification Method (CT) is a commercially available kit with media and 
devices (Appendix 7.3.4). A modified version of the CT method utilising the Cryotop® 
Vitrification device, the CryoLogic Vitrification block (SSV) and the equilibration and 
vitrification solutions from supplier A and C were used. The solutions from suppliers A, B 
and C were used for warming (Appendix 7.3.7 ).  
3.6.3.2.1 Cryotop® Vitrification (Detail Appendix 7.3.5) 
Blastocysts were equilibrated singularly for 15 minutes at room temperature in a 
solution of 8% EG/ DMSO containing osmotic buffer. Unlike the CVM protocol there was 
no artificial collapsing of the blastocoel. The blastocyst was then transferred to a 
vitrification solution containing 16% EG/DMSO with a higher concentration of osmotic 
buffer. After rinsing for 60 seconds the blastocyst was aspirated in a volume < 0.1 µl and 
placed on the tip of the Cryotop® sheet. Excess vitrification solution was removed leaving 
a planar droplet containing the blastocyst. The sheet was then placed against a stainless-
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steel vitrification block, pre-equilibrated in liquid nitrogen. Once vitrified the sheet was 
inserted into a pre-cooled sheath and stored in LN2. 
3.6.3.2.2 Cryotop® Warming (Detail Appendix 7.3.6) 
Single blastocyst warming commenced a minimum 3 hrs prior to the scheduled transfer 
to allow enough time for embryo assessment. Cryotop® sheets holding the blastocysts 
were removed from LN2 and plunged into a solution pre-incubated at 37°C containing an 
osmotic buffer (sucrose or trehalose) for 1 minute. The blastocyst was then moved 
through a series of solutions with decreasing concentrations of osmotic buffer prior to 
moving to BM for culture and survival assessment. 
3.6.4 Survival Assessment 
Blastocysts were observed briefly at 30- and 60-minutes post warming on an inverted 
microscope for commencement of re-expansion defined as the appearance of a cavity 
and/or lineation of trophectoderm cells. Cell degeneration assessment occurred at the 
same time and was observed as highly granular cytoplasm without distinct cell 
membranes. During the first 2 years of the study period, if there was estimation that the 
proportion of viable cells was less than 70%, the blastocyst was deemed not to have 
survived and was not transferred. Due to poor outcomes from blastocysts assessed as 
survived using this criterion alone but not commenced re-expansion within 60 minutes, 
the latter assessment method became the sole survival criterion.  
3.6.5 Endometrial Preparation and Embryo Transfer 
Frozen embryo transfer cycles (FET) were managed either by hormone replacement 
therapy (HRT), low dose stimulation (LDS) or natural (NAT) cycle monitoring. HRT cycles 
involved administration of 4mg TDS Progynova® (Bayer, Australia) for a minimum of 10 
days. Serum E2 was measured on day 10 of the cycle and endometrial quality was 
examined via vaginal ultrasound. When E2 was greater than 800 pmol/l and endometrial 
thickness greater than 8mm, progesterone pessaries 400mg TDS (Orion, Balcatta 
Western Australia) were administered by the patient 3 times daily. The FET was 
scheduled on the sixth day of pessaries. Pessaries were continued until indicated 
otherwise by negative pregnancy result or placental support was initiated. Serum E2 and 
P4 levels were observed 3 days post transfer.  
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Gonal F®was administered for LDS cycles and response monitored using serum E2 levels 
on days 2 and 9. Once E2 level exceeded 500 pmol/l, vaginal ultrasound was used to 
monitor follicular and endometrial growth. When serum E2 levels reached 800IU and 
endometrial thickness reached 8mm, 5000IU hCG (Pregnyl™, human chrionic 
gonadotrophin) was used to trigger ovulation with embryo transfer scheduled for 6 days 
later. Gonadotrophic support was administered, 1500IU/day Pregnyl™ corresponding 
with days 17, 20, 23 and 26 of patient cycle. Serum E2 and P4 were examined 8 days 
post trigger. 
All embryo transfers were conducted using a Guardia™ Access Embryo Transfer Catheter 
from COOK® medical. A 1ml syringe filled with equilibrated culture media was attached 
to the inner sheath and stored in 6%CO2, at 37°C until required. At time of transfer, a 
blastocyst was moved from 20µl droplet into 900µl of culture medium. The embryo was 
loaded into the catheter by filling the inner sheath with pre-equilibrated medium, 
introducing a small air bubble, drawing approximately 5µl of medium into the catheter, 
followed by the embryo with another 5µl of media and another small air bubble. The 
total volume for transfer was approximately 10-15µl. The outer sheath of the catheter 
was placed through the cervix and under ultrasound guidance; the inner sheath was 
passed through and 20-35µl of medium containing the embryo deposited 1 cm back 
from the fundus. The inner and outer sheaths were checked by the scientist post 
transfer to ensure the successful transfer of the embryo. 
Human chorionic gonadotrophin hormone levels higher than 25IU/l indicated a positive 
biochemical pregnancy. Oestradiol and progesterone support was continued in patients 
to ensure adequate support before the placental hCG production shift. Pregnancy 
monitoring continued per practice protocol. Weekly blood tests of serum E2, P4 and hCG 
continued until week 7 of pregnancy when clinical pregnancy was confirmed by the 
presence of a gestational sac and fetal heart via ultrasound. 
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4 RESULTS 
4.1 Patient and Cycle Demographics 
4.1.1 Number of Embryos Transferred 
There were 2466 transfers of either 1 or 2 vitrified/warmed blastocysts resulting in 796 
(32.3%) clinical pregnancies and 751 (30.5%) live born babies. Less than 7% of embryo 
transfers were of 2 blastocysts due to either advanced maternal age or previous failed 
attempts. Table 4-1 shows the proportion of multiple pregnancies was significantly 
greater when 2 blastocysts were transferred compared to one, despite the overall 
clinical pregnancy rate not being significantly greater. The individual embryo outcomes 
(Table 4-2) demonstrate that the embryo implantation rate in the patients receiving two 
blastocysts was significantly lower than those receiving one, however they were also 
significantly older (Table 4-1). Genetically tested, imported, and embryos derived from 
donor oocytes were excluded from the data set to avoid any bias. 
Table 4-1: Pregnancy and multiple rates according to the number of warmed blastocysts 
transferred. Pregnancies were identified with a positive pregnancy test at week 4 and 
confirmed as viable with one or more fetal hearts present at 7 weeks gestation. 
 
Parameter 
No. embryos transferred 
1 2 p-value 
Age at transfer (mean years) 34.5 ± 4.5 36.0 ± 4.4 <0.0001 
No. embryo transfers 2311 155  
No. positive pregnancy tests* 961 (41.6%) 74 (47.7%) >0.133 
No. viable pregnancies* 735 (31.8%) 61 (39.3%)  >0.052 
No. multiple pregnancies** 18 (2.4%) 15 (24.6%) <0.0001 
*per transfer; **per viable pregnancy 
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Table 4-2: Embryo implantation and singleton birth details according to the number of 
warmed blastocysts transferred. 
 
Parameter 
No. embryos transferred 
1 2 p-value 
No. embryos transferred 2311 312  
No. fetal hearts 754 (32.9%) 76 (24.4%) <0.003 
No. babies born* 684 (29.6%) 67 (21.5%) <0.005 
No. boys:girls 344:340 34:33 = 1.0 
Weight at birth (g) 3346 ± 639 3186 ± 683 >0.052 
Gestation (weeks) 38.9 ± 2.4 38.4 ± 2.2 >0.101 
* number of babies born per embryo transferred 
The average gestational age of a multiple delivery was 36 ± 2.1 weeks compared to 39 ± 
2.3 weeks for singleton deliveries. Average birthweight for multiples (2261g ± 498g) was 
also significantly reduced (p<0.0001) when compared to singletons (3376g ± 607g). 
Double embryo transfers were excluded from further analysis due to the reduced 
proportion (6.3%), significantly different outcomes and the inability to trace individual 
blastocysts. 
4.1.2 Type of Transfer Cycle 
Almost half (47.7%) of single embryo transfer cycles were prepared using HRT, 40.0% 
LDS and the remainder being NAT cycles (12.3%). HRT cycles produced significantly less 
viable pregnancies per SET compared to LDS and NAT cycles combined, however the age 
of patients in this group was significantly older (Table 4-3). 
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Table 4-3: Single embryo transfer pregnancy rates and outcomes according to the type 
of transfer cycle. Cycles were following hormone replacement therapy (HRT), low dose 
stimulation (LDS) or unstimulated (natural). 
 
Parameter 
Cycle type 
HRT LDS Natural p-value 
Age at transfer (mean years) 35.2 ± 4.6 33.9 ± 4.1 33.5 ± 4.5 <0.0001** 
No. transfers 1103 925 283  
No. positive pregnancy tests 422 (38.3%) 406 (43.9%) 133 (47.0%) <0.006* 
No. viable pregnancies 302 (27.4%) 321 (34.7%) 112 (39.6%) <0.0001* 
*based on Bonferroni sig level p=0.017 for multiple comparisons, LDS (p=0.0111, 0.0004) and 
Natural (p=0.0080, <0.0001) cycles produced significantly greater positive pregnancy tests and 
viable pregnancies respectively than HRT cycles. There was no significant difference in positive 
pregnancy tests (p<0.3961) and viable pregnancies (p<0.1542) between LDS and Natural cycles. 
** The average age of patients was significantly different between both LDS (p<0.0001) and 
Natural (p<0.0001) compared to HRT cycles however there was no significant difference 
(p>0.3730) between LDS and Natural cycles.  
The average weight at birth and gestational period was not significantly different when 
comparing the type of transfer cycle but the number of fetal hearts and babies born in 
proportion to SET was significantly lower in the HRT group (Table 4-4). 
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Table 4-4: Embryo implantation and birth details according to the type of transfer cycle. 
Cycles were following hormone replacement therapy (HRT), low dose stimulation (LDS) 
or unstimulated (natural). 
 
Parameter 
Cycle type 
HRT LDS Natural p-value 
No. embryos transferred 1103 925 283  
No. fetal hearts 311 (28.2%) 327 (35.4%) 116 (41.0%) <0.0001* 
No. babies born 280 (25.4%) 299 (32.3%) 105 (37.1%) <0.0001* 
Weight at birth (g) 3307 ± 673 3355 ± 595 3423 ± 666 0.2767 
Gestation (weeks) 38.8 ± 2.8 38.9 ± 1.9 39.1 ± 2.5 0.5475 
*based on Bonferroni sig level p=0.017 for multiple comparisons, LDS (p<0.0007, <0.0007) and 
Natural cycles (p<0.0001, <0.0001) produced a significantly greater proportion of fetal hearts 
and babies born respectively than HRT cycles. There was no significant difference in the 
proportion of fetal hearts (p<0.0985) and babies born (p<0.1563) between LDS and Natural 
cycles. 
4.1.3 Aetiology of Infertility 
The cause of infertility, as diagnosed prior to the commencement of IVF treatment, did 
not significantly influence the outcome of single frozen embryo transfers (Table 4-5). 
More than half the embryos were from couples with male infertility only or idiopathic 
infertility. 
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Table 4-5: The relationship between aetiology of infertility and pregnancy following a 
single transfer of a warmed blastocyst. 
Aetiology Transfers Viable pregnancies* Deliveries** 
Male and female factors 467 (20%) 127 (27.2%) 122 (26.1%) 
Female factors only 447 (19%) 138 (30.9%) 117 (26.2%) 
Male factors only 638 (28%) 216 (33.9%) 192 (30.1%) 
Tubal factors 118 (5%) 44 (37.3%) 41 (34.7%) 
Unexplained 637 (28%) 210 (33.0%) 190 (29.8%) 
Total 2311 735 (31.8%) 662 (28.6%) 
* p>0.0912, ** p>0.1977 
Based on Bonferroni sig level p<0.005 for multiple comparisons (10) there was no significant 
difference in viable pregnancies (p>0.0216) or deliveries (p>0.0797) relative to patient aetiology. 
4.1.4 Transfer Attempt 
The number of previous embryo transfers a patient had received, whether successful 
and producing a viable pregnancy, or not implanting, is associated with the implantation 
rate. 1st transfer patients have not had a prior fresh transfer either due to patient choice 
or medical reasons. An increased progesterone level (prior to hCG administration) and 
risk of OHSS are the most common reasons for a freeze all cycle. Table 4-6 describes the 
reduced proportion of deliveries as the transfer attempts increase. 
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Table 4-6: Impact on outcome relative to the rank of transfer attempt 
Parameter 
Single embryo transfer rank  
Total 1 2 3-5 6-20 
Average age (mean 
years) 
32.4 ± 4.2 33.1 ± 4.5 33.6 ± 4.5 35.0 ± 3.9 33.5 ± 4.5 
No. transfers (SET) 287 802 958 264 2311 
No. viable 
pregnancies* 
120 (41.8%) 264 (32.9%) 287 (30.0%) 64 (24.2%) 735 (31.8%) 
No. deliveries* 111 (38.7%) 242 (30.2%) 254 (26.5%) 55 (20.8%) 662 (28.6%) 
Based on Bonferroni sig level p<0.0083 for multiple comparisons there was no significant 
difference in age between 1st and 2nd (p<0.0951) or 2nd and 3-5th (p<0.0821) transfer attempts. 
All other group comparisons of age were significant (p<0.0003). 1st transfer viable pregnancy and 
delivery rate was significantly (p<0.0002, p<0.0001) greater than 3-5 or 6-20 transfer attempts. 
All other transfer rank comparisons were not significant (p>0.0084). 
4.1.5 Impact of Age 
The proportion of embryo transfers resulting in viable pregnancies and deliveries 
according to the woman’s age is shown in Table 4-7. Whilst there was no difference 
between the women <30 yrs and 30-34 yrs, there were progressive and significant 
reductions in rates of pregnancy and delivery for those aged 35-39 yrs and ≥ 40 yrs. 
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Table 4-7: Impact of the age of the woman at vitrification upon blastocyst survival and 
implantation. 
Parameter 
Age of woman at vitrification (years)  
Total <30 30-34 35-39 ≥40 
No. transfers (SET) 465 844 794 208 2311 
No. viable pregnancies* 173 (37.2%) 291 (34.5%) 229 (28.9%) 42 (20.2%) 735 (31.8%) 
No. deliveries* 166 (35.7%) 265 (31.4%) 199 (25.1%) 32 (15.4%) 662 (28.6%) 
* p<0.0001 
Based on Bonferroni sig level p<0.0083 for multiple comparisons there was no significant 
difference in viable pregnancies (p>0.3537) or the number of deliveries (p>0.1277) between 
patients aged less than 30 and between 30 and 34. The number of deliveries between all other 
age groups was significantly different (p<0.0053). 
4.1.6 Logistic Regression of patient and cycle parameters. 
Maternal age, cycle type, and transfer order independently influence embryo transfer 
outcomes as shown by the odds ratios (Table 4-8). Patients less than or equal to 38 years 
of age at the time of vitrification are more than twice as likely to achieve the delivery of 
a baby than those older than 38. This trend is maintained despite adjusting for cycle type 
and transfer attempt (Table 4-9). The shift in odds ratio for all three independent 
variables is less than 10% using multiple regression analysis. This indicates the effect of 
confounding between cycle type, age and transfer attempt is minimal. 
Table 4-8: Simple regression results for age, cycle and transfer rank. 
Predictor Value p-value OR CI 
Age ≤ 38 years < 0.0000 2.1752 1.6020 2.9534 
Cycle No HRT < 0.0000 1.4770 1.2327 1.7696 
Transfer attempt ≤ 2 < 0.0002 1.4034 1.1732 1.6788 
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Table 4-9: Multiple logistic regression results controlling for age, cycle and transfer rank. 
Predictor Value p-value OR CI 
Age ≤ 38 years < 0.0000 2.0086 (7.7%) 1.4755 2.7344 
Cycle No HRT < 0.0005 1.3832 (6.4%) 1.1517 1.6611 
Transfer attempt ≤ 2 < 0.0026 1.3220 (5.8%) 1.1027 1.5850 
Percentage in parentheses represents the deviation from simple regression (Table 4-8) and 
multiple regression controlling for the other 2 variables. If >10% there is evidence of 
confounding.  
4.2 Blastocyst Specific Variables 
4.2.1 Age of embryo at time of vitrification (Day 5 vs Day 6) 
In a fresh cycle, embryo selection for transfer and vitrification occurs initially on Day 5 
and if nothing is suitable, subsequently on Day 6. A day 5 embryo has a typical age of 
118-125 hrs post insemination and a day 6 embryo 138-143 hrs post insemination. The 
survival, viable pregnancy and delivery rates are significantly greater for Day 5 embryos 
within the context of this protocol (Table 4-10). 
 
Table 4-10: The survival after warming and subsequent implantation of blastocysts 
vitrified on Day 5 vs Day 6 
 D5 D6 P value 
# warmed 2397 580  
#survived 2130 (88.9%) 493 (85%) <0.0102 
#SET 1887 424  
#viable pregs 643 (34.1%) 92 (21.7%) <0.0000 
#deliveries 580 (30.7%) 82 (19.3%) <0.0000 
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4.2.2 Blastocyst grade and expansion level relative to day of vitrification. 
In addition to the age of the blastocyst, the morphological variables, cell quality (grade1-
2) and the level of expansion differed at the time of vitrification. There was no significant 
difference in survival (p > 0.6458) or live birth rate (p > 0.3161) between grade 1 and 2 
blastocysts at the early stages of expansion on day 5 (Table 4-11). The difference in live 
birth rate between grade 1 and 2 blastocysts became significant for more expanded 
blastocysts on day 5 of development. There were too few blastocysts at the early 
expansion stages vitrified on day 6 to make a comparison with just one grade one 
blastocyst being transferred (Table 4-12). There were no significant differences in 
survival or live birth rate between grade 1 or 2 blastocysts at the more expanded stages 
on day 6. The proportion of grade 1 blastocysts on day 5 (31.5%) was significantly 
greater (p<0.0000) than that of day 6 (10.3%).  
Table 4-11: The survival after warming and subsequent implantation of blastocysts 
transferred on Day 5. Embryos stratified as either non-expanded or expanded/hatching 
and grade 1 or 2. 
Expansion Early blastocyst (EB) to Blastocyst(B) 
Expanded Blastocyst (XB) to Fully 
Hatched Blastocyst (FHB) 
Grade 1 2 1 2 
# warmed 92 566 663 1076 
#survived 84 (91.3%) 508 (89.8%) 591 (89.1%) 947 (88.0%) 
#SET 75 432 547 833 
#viable pregs 23 (30.7%) 109 (25.2%) 236 (43.1%) 275 (29.0%) 
#deliveries 21 (28.0%) 98 (22.7%) 216 (39.5%)* 245 (25.8%)* 
* P < 0.0007 
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Table 4-12: The survival after warming and subsequent implantation of blastocysts 
transferred on Day 6. Embryos stratified as either non-expanded or expanded/hatching 
and grade 1 or 2. 
Expansion EB to B XB to FHB 
Grade 1 2 1 2 
# warmed 1 31 59 489 
#survived 1 (100%) 29 (93.5%) 52 (88.1%) 411 (84.0%) 
#SET 1 26 47 350 
#viable pregs 0 (0%) 4 (15.4%) 14 (29.8%) 74 (21.1%) 
#deliveries 0 (0%) 4 (15.4%) 11 (23.4%) 67 (19.1%) 
 
4.2.3 Logistic Regression of Embryo Specific Variables. 
The day of vitrification, blastocyst grade and degree of expansion are independently 
associated with live delivery as an embryo transfer outcome as shown by the odds ratios 
in Table 4-13. Using multiple regression analysis, Day 5, Grade 1 Blastocysts that have 
reached the expanded/hatching stage have an 80% greater chance of continuing to a 
baby than Grade 1 expanded blastocysts on Day 6 (Table 4-14). Grade 1, Day 5 
Blastocysts that have reached the expanded/hatching stage have a 51% greater chance 
of continuing to a baby than Grade 2 Blastocysts that are also at the expanded/hatching 
stage on Day5. Blastocysts that have reached the expanded/hatching stage on Day 5 and 
are grade 1 have a 47% greater chance of continuing to a baby than non-expanded 
blastocysts. There was a significant reduction (13.5%) in the OR of the morphology grade 
when controlling for day of vitrification and expansion level suggesting some 
confounding (Table 4-14). 
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Table 4-13 Simple regression results for a comparison of day of vitrification, embryo 
grade and expansion level on delivery rates. 
Predictor Value p-value OR 95% CI 
Day of vitrification 5 < 0.0000 1.8508 1.4270 2.4006 
Morphology Grade 1 < 0.0000 1.7473 1.4417 2.1175 
Expansion level ≥XB < 0.0009 1.4626 1.1675 1.8323 
 
Table 4-14 Multiple logistic regression results controlling for day of vitrification, embryo 
grade and expansion level relative to delivery rates. 
Predictor Value p-value OR 95% CI 
Day of vitrification 5 <0.0000 1.7962 (-3.0%) 1.3728 2.3503 
Morphology Grade 1 <0.0001 1.5120 (-13.5%) 1.2373 1.8475 
Expansion level ≥XB <0.0012 1.4747 (+0.7%) 1.1663 1.8647 
Percentage in parentheses represents the deviation from simple regression (Table 4-13) and 
multiple regression controlling for the other 2 variables. If >10% there is evidence of 
confounding.  
 
Comparisons using binary logistic regression to identify individual confounding showed a 
significant reduction in the OR of day of vitrification when controlling for morphology 
grade. Day 5 grade 1 blastocysts have a 64% greater chance of continuing to a baby than 
day 6 grade 1 blastocysts (Table 4-15). However, a greater proportion of day 6 
blastocysts are morphology grade 2 (376/424, 89%) compared to day 5 blastocysts 
(1265/1887, 67%). Within blastocysts vitrified on Day 5 the morphology grade 1 
blastocysts had a 64% greater chance to continue to a baby than morphology grade 2 
blastocysts on the same day (Table 4-15). 
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Table 4-15 Binary logistic regression of day of vitrification and morphology grade relative 
to delivery rates 
Predictor Value p-value OR 95% CI 
Day of vitrification 5 <0.0002 1.6404 (-11.4%) 1.2604 2.1349 
Morphology Grade 1 <0.0000 1.6299 (-6.7%) 1.3406 1.9816 
 
More expanded grade 1 blastocysts had a 32% greater chance of continuing to a baby 
than non-expanded grade 1 blastocysts (Table 4-16). Morphology grade had more than 
double the effect of expansion as grade 1 expanded blastocysts had a 67% greater 
chance of continuing to a baby than grade 2 expanded blastocysts. 
Table 4-16 Binary logistic regression of expansion level and morphology grade relative to 
delivery rates 
Predictor Value p-value OR 95% CI 
Expansion level ≥XB <0.0173 1.3216 (-9.6%) 1.0504 1.6628 
Morphology Grade 1 <0.0000 1.6731 (-4.2%) 1.3762 2.0339 
 
Expanded blastocysts on day 5 were more than twice as likely to continue to a baby than 
expanded blastocysts on day 6 of development (Table 4-17). Expanded blastocysts on 
day 5 of development had a 63% greater chance of continuing to a baby than non-
expanded blastocysts on day 5. However, a greater proportion of day 6 blastocysts were 
expanded (397/424, 93%) compared to day 5 blastocysts (1380/1887, 73%). 
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Table 4-17 Binary logistic regression day of vitrification and expansion level relative to 
delivery rates 
Predictor Value p-value OR 95% CI 
Day of vitrification 5 <0.0000 2.0100 (+7.9%) 1.5456 2.6140 
Expansion level ≥XB <0.0000 1.6313 (+10.3%) 1.2976 2.0509 
4.2.4 Ranking of implantation potential 
Combining the survival rates and subsequent SET live delivery rates it is possible to 
construct a ranking table that provides a guide as to the probability of success of an 
embryo prior to choosing it to warm (Table 4-18). This table shows the improved success 
rates according to the day of vitrification, the morphology grade and to a lesser degree, 
expansion level. 
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Table 4-18 Blastocyst rankings according to blastocyst specific variables 
Category of 
embryo 
SET Viable pregnancies Deliveries Delivery rate of warmed 
blastocysts 
D5HB1 195 92 (47.2%) 84 (43.1%) 39.9% 
D5XB1 342 140 (40.9%) 128 (37.4%) 32.6% 
D5B1 67 22 (32.8%) 20 (29.9%) 27.1% 
D5XB2 641 214 (33.4%) 193 (30.1%) 26.4% 
D5HB2 187 61 (32.6%) 52 (27.8%) 24.6% 
D5EB2 87 26 (29.9%) 25 (28.7%) 23.4% 
D6HB1 21 6 (28.6%) 5 (23.8%) 20.2% 
D5B2 345 83 (24.1%) 73 (21.2%) 19.5% 
D6XB1 24 7 (29.2%) 5 (20.8%) 18.7% 
D6XB2 195 41 (21.0%) 38 (19.5%) 16.7% 
D6HB2 128 28 (21.9%) 25 (19.5%) 15.8% 
D6B2 24 4 (16.7%) 4 (16.7%) 15.5% 
D6FHB2 27 5 (18.5%) 4 (14.8%) 13.5% 
D5/D6 refers to day of vitrification 
EB early blastocyst, B blastocyst, XB expanded blastocyst, HB hatching blastocyst, FHB fully 
hatched blastocyst 
1/2 refers to embryo grade  
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4.3 Vitrification/Warming Technique Results 
4.3.1 Vitrification Device 
The change in vitrification device and technique during the data collection period 
resulted in an increasing proportion of CT warms occurring from 2010 through to 2015 
(Figure 4-1). This was expected as there is a delay in pregnant patients returning to use 
any remaining embryos.  
Figure 4-1 The proportion of warms with the Cryotop® and FibreplugTM devices. 
 
The overall survival rate of blastocysts vitrified on the Cryotop® device was 91.2% 
(1577/1730) which was significantly greater (p<0.0001) than the 83.9% (1046/1247) for 
blastocysts vitrified on the FibreplugTM device. The live delivery rate from SET’s however 
was not significantly different (p>0.3196) between the two devices (Cryotop® 422/1436, 
29.4%; FibreplugTM 240/875, 27.4%). The average age of the patients at the time of 
vitrification was also not significantly different (p>0.2273) between groups (Cryotop®, 
33.5 ± 4.5; FibreplugTM, 33.7 ± 4.4). The significant improvement in survival rate was not 
seen when controlling for media type (p>0.2016). The survival rate of blastocysts 
vitrified and warmed using only media from supplier A on the Cryotop device was 86.2%. 
Using the same media combination with FibreplugTM the survival rate was 83.8%. 
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4.3.2 Vitrification/Warming Media 
Vitrification and warming media used for both devices were from three different 
suppliers during the data collection period (Appendix 7.3.7). All vitrification media 
contained the cryoprotectants ethylene glycol and DMSO with either sucrose or 
trehalose being used as the osmotic buffer. The warming media consisted of a base 
media with differing concentrations of osmotic buffer. Most blastocysts vitrified on the 
FibreplugTM with media from supplier A were warmed using media from the same 
supplier and therefore it was not possible to make comparisons with media suppliers 
using this device (Table 4-19). 
Table 4-19 The survival and implantation of blastocysts vitrified on the FibreplugTM device 
using vitrification media from supplier A. Blastocysts were then warmed in media from 
suppliers A, B and C. 
 
Parameter 
Warming Media  
Total A B C 
Age (av.yrs.) 33.8 ± 4.4 32 ± 3.2 32.4 ± 3.6 33.7 ± 4.4 
# warmed 1185 12 50 1247 
#survived 993 11 42 1046 (83.9%) 
#SET 828 11 36 875 
#viable pregs 241 (29.1%) 4 (36.4%) 16 (44.4%) 261 (29.8%) 
#deliveries 222 (26.8%) 4 (36.4%) 14 (38.9%) 240 (27.4%) 
 
Vitrification on the CT device used media from suppliers A (Table 4-20) and C (Table 
4-21) with subsequent warming with media from suppliers A, B, C and B and C 
respectively. There was no significant difference in delivery rates between any of the 
media however the survival rate was significantly greater using warming media from 
supplier B. This difference persisted whether vitrification media from supplier A 
(p<0.0000) or C (p<0.0195) was used. 
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Table 4-20 The survival and implantation of blastocysts vitrified on the Cryotop® device 
using vitrification media from supplier A. Blastocysts were then warmed in media from 
suppliers A, B and C. 
 
Parameter 
Warming Media  
Total A B C 
Age (av.yrs.) 33.6 ± 4.4 33.1 ± 4.2 33.2 ± 4.8 33.3 ± 4.5 
# warmed 558 316 334 1208 
#survived 481 (86.2%)* 301 (95.3%)* 304 (91.1%) 1086 (89.9%) 
#SET 423 277 273 973 
#viable pregs 127 (30.0%) 97 (35.0%) 97 (35.5%) 321 (33.0%) 
#deliveries 109 (25.8%) 89 (32.1%) 85 (31.1%) 283 (29.1%) 
*Based on Bonferroni sig level p<0.0167 for multiple comparisons the survival rate using 
warming media from supplier B was significantly higher (p<0.0000) than that using warming 
media from supplier A. There was no significant difference in delivery rate between any of the 
groups (p>0.0867). 
Table 4-21 The survival and implantation of blastocysts vitrified on the Cryotop® device 
using vitrification media from supplier C. Blastocysts were then warmed in media from 
suppliers B or C. 
 
Parameter 
Warming Media  
Total B C 
Age (av.yrs.) 34.0 ± 4.2 33.5 ± 4.8 33.7 ± 4.6 
# warmed 190 332 522 
#survived 185 (97.4%)* 306 (92.2%)* 491 (94.1%) 
#SET 176 287 463 
#viable pregs 66 (37.5%) 87 (30.3%) 153 (33.0%) 
#deliveries 60 (34.1%) 79 (27.5%) 139 (30.0%) 
*p<0.0195 
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4.4 Embryo assessment prior to transfer 
During the early part of the data collection period, 2008-2009, the sole survival criterion 
was the cell degeneration level. Any blastocyst with less than 70% cell survival was 
considered not to have survived and therefore was not transferred. Blastocysts with 
levels of cell degeneration greater than 5% had significantly poorer success rates than 
those with less than 5% (Table 4-22). This form of assessment was accompanied by 
observations of re-expansion (Figure 4-2). Re-expansion became the sole assessment 
tool for survival in 2010. It was easier to quantify, and early observations revealed 
extremely poor success with blastocysts that took longer than 60 minutes to begin the 
re-expansion process (Table 4-23, Figure 4-3). This effect was also seen on outcomes 
when comparing blastocysts that commenced re-expansion within 30 minutes to those 
commencing between 30-60 minutes. The commencement of re-expansion was 
demonstrated by the development of a blastocoel and/or lineation of trophectoderm 
cells (Figure 4-4).  
Table 4-22 Proportion of cells surviving relative to the implantation and pregnancy 
outcome of warmed blastocysts. 
Parameter 
Cell survival (%) 
p-value 
70-79 80-94 95-100 
Age (av.yrs.) 34.4 ± 4.7 33.9 ± 4.4* 33.3 ± 4.5* 0.0082 
#warmed 71 634 1912  
#SET** 47 561 1692  
#viable pregs 5 (10.6%) 132 (23.5%) 593 (35.0%) <0.0000 
# deliveries 5 (10.6%) ** 119 (21.2%) ** 533 (31.5%) <0.0000 
* Based on Bonferroni sig level p<0.0167 for multiple comparisons there was a significantly 
greater proportion of older patients in the 80-94% group than the 95-100% group (p<0.0165). 
**There was no significant difference in the delivery rate between blastocysts with 70-79% cell 
survival and those with 80-94% survival (p>0.0839). Blastocysts with 95-100% survival had a 
significantly greater delivery rate than the 70-79 group (p<0.0023) and the 80-94 group 
(p<0.0000). ** x11 cell survival unknown as not recorded. 
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Table 4-23 Time taken to begin re-expansion after warming relative to the implantation 
and pregnancy outcome of warmed blastocysts (only recorded 2010 onwards).  
Parameter 
Time to start re-expansion (mins) 
p-value 
<30 30-60 >60 
Age (av.yrs.) 33.4 ± 4.5 33.2 ± 4.3 33.3 ± 4.0 0.7268 
#warmed 1475 456 391 2322 
#SET 1329 (90.1%) 411 (90.1%) 25 (6.4%)+ 1765 
#viable pregs 458 (34.5%) 120 (29.2%) 1 (4%) <0.0012 
# deliveries 410 (30.9%)* 105 (25.5%)* 1 (4%) <0.0024 
*Blastocysts commencing re-expansion within 30 minutes post warm had a significantly greater 
delivery rate than those commencing between 30- and 60-minutes post warm (p<0.0399). 
+ The practice of transferring blastocysts that commenced re-expansion more than 60 minutes 
after the warm ceased early in the study period due to the poorer results with these embryos. 
Figure 4-2 Commencement of re-expansion 
 
Arrows indicate evidence of re-expansion commencing.  
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Figure 4-3 A blastocyst failing to commence re-expansion after warming. 
 
Figure 4-4 Re-expansion within 30 minutes for a full blastocyst (top row) and a fully 
hatched blastocyst (bottom row) 
 
The rate of re-expansion for fully hatched blastocysts was relatively slower than the 
earlier stages of blastocyst development and had the greatest proportion (89%) that 
commenced re-expansion between 30 and 60 minutes. (Figure 4-5). 
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Figure 4-5 Time to commence re-expansion across different blastocyst stages 
 
Figure 4-6 Rate of re-expansion relative to vitrification device. 
 
A significantly (p<0.03) greater proportion of blastocysts vitrified on the Cryotop® (CT) 
device re-expanded within the first 30 minutes post warming when compared to those 
vitrified on the FibreplugTM (FP)(Figure 4-6).  
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4.4.1 Multiple Logistic Regression of embryo assessment criteria 
Simple regression analysis of cell degeneration and re-expansion shows that both 
variables are significantly associated with delivery rates (Table 4-24). Binary logistic 
regression controlling for each variable, however, shows significant confounding 
between the two variables (Table 4-25). Within blastocysts that re-expand in ≤ 30 
minutes, those with ≥ 95% cell survival after warming have a 57% greater chance of 
progressing to a baby than those with between 70 and 94% cell survival.  Within 
blastocysts that have ≥ 95% cell survival, however, there is no significant difference in 
delivery rate between those that commence re-expansion in ≤ 30 minutes to those that 
commence re-expansion between 30 and 60 minutes. 
Table 4-24 Simple regression results for a comparison of cell degeneration and re-
expansion assessment criteria on delivery rates. 
Predictor Value p-value OR 95% CI 
Cell degeneration ≥95% <0.0000 1.7950 1.4372 2.2420 
Re-expansion ≤30min <0.0399 1.3002 1.0122 1.6701 
Table 4-25 Binary logistic regression results controlling for cell degeneration and re-
expansion. 
Predictor Value p-value OR 95% CI 
Cell degeneration ≥95% <0.0005 1.5719 (12.4%)* 1.2185 2.0280 
Re-expansion ≤30min >0.3499 1.1308 (13.0%)* 0.8738 1.4634 
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4.5 Time interval between warm and transfer 
An advantage of assessing blastocysts after warming compared to cleavage stage 
embryos is the early evidence of the re-commencement of cellular activity. This gives an 
embryologist the ability to select or de-select a blastocyst within 60 minutes of warming 
it. Despite this shorter time frame, embryo transfer appointment times should allow ≥ 
3hrs for a suitable blastocyst to be assessed and selected for transfer. This provides for 
the possibility of needing to warm subsequent blastocysts. The warming of subsequent 
blastocysts and different scheduling times alters the time between the warm and the 
transfer (Table 4-26). 
Table 4-26 The impact of time between starting the warm and transfer of vitrified 
blastocysts. 
Parameter 
Time between warm and transfer (hrs) 
0-1 2 3 4 5 6 ≥7 
#SET 68 433 708 580 336 86 100 
#viable pregs 
20 
(29.4%) 
139 
(32.1%) 
218 
(30.8%) 
201 
(34.7%) 
104 
(31.0%) 
26 
(30.2%) 
27 
(27.0%) 
# deliveries 
19 
(27.9%) 
124 
(28.7%) 
192 
(27.1%) 
182 
(31.4%) 
96 
(28.6%) 
23 
(26.7%) 
26 
(26.0%) 
Coefficient of determination, R2=0.1288 
 p=0.4291 
There was no linear relationship when comparing the time difference between warming 
a blastocyst and its eventual transfer. Only 13% of the variance in transfer outcome 
could be explained by the time interval between the warm of the blastocyst and its 
transfer. 
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5 DISCUSSION 
5.1 Clinical value of embryo cryopreservation 
The original clinical benefit of embryo cryopreservation was to utilise all embryos 
produced from an oocyte collection cycle using exogenous gonadotrophins without 
increasing the probability of a multiple pregnancy (Cohen et al., 1985). This strategy also 
improved the cumulative pregnancy rate from an oocyte retrieval cycle and reduced 
overall treatment costs (Kjellberg, Carlsson, & Bergh, 2006). In this present study the 
majority (> 80%) of embryos cryopreserved were from cycles that also had fresh embryo 
transfers and embryos were vitrified for future use. Embryo cryopreservation is also 
utilised for oocyte donor/recipient cycles to assist with cycle synchronisation but early 
attempts proved difficult to justify due to poor embryo survival rates of less than 50% 
(Devroey & Pados, 1998).  More recently with improved cryopreservation techniques 
and better survival rates above 90%, embryo cryopreservation in donor/recipient cycles 
is more commonly used (Cobo et al., 2012). Of the 2821 oocyte recipient cycles 
performed during 2016 in Australia and New Zealand, 53.5% were thaw cycles and the 
live delivery rate was higher from thaw (26.2%) than fresh (14.5%) cycles (Fitzgerald et 
al., 2018). The use of thaw cycles for oocyte/embryo donation also allows for a 
quarantine period to reduce the risks of transmission of infectious diseases from donor 
to recipient (Hamer, Horne, Pease, Matson, & Lieberman, 1995).  In this present study, 
donor recipient embryos were excluded to avoid bias. If facilities and logistics did not 
allow for blastocyst culture that can further discriminate viable embryos, 
cryopreservation at early embryo stages was useful (Mandelbaum et al., 1987). It has 
also been used to rescue cleavage stage embryos that were classified as unusable due to 
poor morphological grades. If they developed to blastocysts they could be cryopreserved 
at the blastocyst stage and utilised in a later cycle if needed (Hartshorne, Elder, Crow, 
Dyson, & Edwards, 1991). During this present study facilities were available for safe 
blastocyst culture and greater than 90% of embryo transfers were of blastocysts. 
Embryo cryopreservation has also been utilised to supposedly improve 
embryo/endometrium synchronicity. Asynchrony due to a pre-ovulatory progesterone 
rise during ovarian stimulation has been shown to reduce the success of fresh embryo 
transfers (Bosch et al., 2010) and be improved by embryo cryopreservation and 
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subsequent transfer in a cycle specifically programmed for embryo transfer (Shapiro et 
al., 2010). Data in this present study did not discriminate for freeze all indications, 
however it is estimated that less than 5% of embryos were cryopreserved due to a 
premature progesterone rise. Slower developing blastocysts have been shown to have 
improved outcomes by cryopreserving and replacement in a later more synchronised 
cycle (Kaye et al., 2017). In this present study slower developing blastocysts (day 6) had 
a significantly reduced delivery rate despite being transferred in a day 5 endometrium of 
a replacement cycle (19.3% vs 30.7%). Embryo cryopreservation can also be used to 
preserve fertility in patients with impending treatment for conditions requiring the use 
of gonadotoxic agents that increase the risk of developing premature ovarian failure and 
infertility (Bedoschi & Oktay, 2013). This may be neoplasia or non-oncological systemic 
autoimmune or haematological conditions (Gidoni, Holzer, Tulandi, & Tan, 2008). The 
increasing success of oocyte vitrification has led to more fertility preservation occurring 
at the oocyte level. This can be performed for younger patients as it avoids the need for 
a donor/partner at the time of preservation and also avoids the problem of having 
excess embryos in storage after completing a family (Robertson, 2014; Seshadri et al., 
2018). The concordant advances in IVF of extended culture, trophectoderm biopsy, next 
generation sequencing (NGS) techniques for genetic screening of all 24 chromosome 
types and blastocyst vitrification have resulted in the increasing use of freeze-all cycles 
for pre-implantation genetic testing (Coates et al., 2017). Coates et al (2017) performed 
a randomised controlled trial of fresh vs frozen euploid blastocyst transfers and found 
no significant difference in live birth rates but more patients reached the stage of 
euploid embryo transfer as both test results for day 5 and 6 blastocysts were available. 
As the analysis took 17 hrs, only day 5 blastocysts could be used for biopsy and 
transferred fresh prior to 12 pm on day 6. The costs to the patient are kept to a 
minimum as biopsied cells can be sent to larger volume genetic testing laboratories 
where batching of samples is possible. In Australian and New Zealand IVF units there 
was an increase of 26.8% in cycles using pre-implantation genetic testing (PGT) during 
2016 and 39.2% were the result of freeze-all cycles (Fitzgerald et al., 2018). In this 
present study, biopsied embryos were excluded to avoid the bias from improved 
outcomes of known euploid embryos. 
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The most prevalent use of the freeze-all embryos strategy is in managing the iatrogenic 
complication of ovarian stimulation, ovarian hyperstimulation syndrome (OHSS) 
(Horwath, Check, Choe, Wilson, & Amui, 2005; Shin, Jeong, Nho, & Jee, 2018).  The 
incidence of mild to severe OHSS has been reported as being between 3.1% and 8% of 
IVF cycles (Delvigne & Rozenberg, 2002), however the validity of reporting is 
questionable for mild to moderate forms of the syndrome (Fernandez-Sanchez et al., 
2019). In Australia and New Zealand 0.5% of cycles proceeding to egg collection in 2016 
were reported as being admitted to hospital for treatment and the frequency of 
admissions was closely correlated with the number of oocytes collected (Fitzgerald et 
al., 2018).  A freeze-all approach to managing OHSS reduces endogenous hCG exposure 
and subsequent elevation of VEGF (vascular endothelial growth factor) from the corpora 
lutea and is one of the most effective strategies to prevent severe forms of OHSS 
(Griesinger et al., 2007; Nelson, 2017). More than 12% (287/2311) of single embryo 
transfers in this present study were first time transfers and therefore from freeze all 
cycles. Subsequent transfers could also be from an original pool of embryos from a 
freeze all cycle. 
5.2 Vitrification as a method of choice 
Slow freezing of human embryos takes more than 2 hours and requires the use of a 
relatively expensive programmable freezer (Mukaida et al., 1998). Soon after the first 
pregnancy utilising slow freezing in human embryos, shorter protocols were being 
devised using an interrupted cooling step and ultrarapid freezing (Gordts, Roziers, 
Campo, & Noto, 1990; Trounson & Mohr, 1983; Trounson, Peura, Freemann, & Kirby, 
1988). Poor survival and implantation rates along with regulatory constraints on human 
embryo cryopreservation trials resulted in most IVF units deferring to the more 
successful slow freezing techniques at this time (Friedler, Giudice, & Lamb, 1988; 
Trounson & Sjoblom, 1988).  
Due to the advantage of possibly avoiding ice crystal formation during vitrification, 
further studies were being conducted on other mammalian species to refine the 
concentrations and types of CPA’s being used (Kasai, 1996). At a similar time blastocyst 
culture became more prevalent with the introduction of stage specific media, the CPA 
combination of EG and DMSO with a step-wise exposure was proving successful for 
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blastocyst vitrification (Lane et al., 1999; Mukaida et al., 2001; Reed, Lane, Gardner, 
Jensen, & Thompson, 2002). Stage specific media was used for the culture of the 
embryos in this present study with EG and DMSO as the cryoprotectants. Despite 
consistent use of these products there was no consistency in the methodology being 
used for the clinical application of blastocyst vitrification and implementation was 
minimal (Vajta & Nagy, 2006). The development of suitable commercially available 
carrier devices that minimised the volume of the suspension containing the embryo and 
hence increased cooling and warming rates ultimately resulted in a widespread adoption 
of vitrification of human embryos (Kuwayama, 2007). Current vitrification techniques 
utilising these devices also provide for a reduced footprint, take up less storage space 
and reduce risk by reducing embryo handling (Liebermann, 2017). The Fibreplug 
vitrification system for blastocysts was established at Hollywood Fertility Centre in 2007. 
5.3 Patient and Cycle Demographics 
5.3.1 Single Embryo Transfer 
There is an ongoing trend of safer embryo transfer practices in Australia. The proportion 
of thaw cycles with a double embryo transfer (DET) in Australia and New Zealand during 
2016 was 8.2% (Fitzgerald et al., 2018). This is a direct result of supportive public funding 
for ART and to a lesser extent, clinical guidelines and educational campaigns (Chambers 
et al., 2013). All ART units in Australia are required by federal law (Research Involving 
Human Embryos Act 2004) to be issued a license to practice by the Reproductive 
Technology Accreditation Committee (RTAC). License holders comply with the RTAC 
Code of Practice that includes measures to reduce the incidence of DET. The latest 
version of the code requires units to recommend only one embryo be transferred to 
patients aged less than 35 years in their first cycle. During the data collection period of 
this present study (2008 to 2015) the proportion was 6.3%. Despite the additional 
embryo, the delivery rate for the Australia and New Zealand data was lower than SET 
(26.3% vs 28.6%). The main reason for this is that a higher proportion of patients 35 
years of age or older received a DET (15.7%) compared to those under 35 (7%) 
(Fitzgerald et al., 2018). The multiple pregnancy rates for SET vs DET in this present study 
were 2.4% and 24.6% respectively and this closely aligns with national data (Fitzgerald et 
al., 2018). Further efforts are required in selecting the right patients for DET, if any. The 
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use of a prediction model applying age, embryo score, ovarian sensitivity and treatment 
history has been shown to reduce the multiple rates from 25.2% to 3.8% for early day 2 
embryo transfers (Vaegter et al., 2019). 
5.3.2 Perinatal outcomes 
The average gestational period (38.9 weeks) and birth weight (3346g) for SET singleton 
pregnancies in this present study was similar to that of all singleton births in the 
Australian population (38.6 weeks and 3372g)  (Australian Institute of Health and 
Welfare, 2018). Despite this similarity the average maternal age of the patients with a 
singleton delivery in this cohort was 33.6 years at the time of the transfer compared to 
30.5 years in the Australian population. Both the gestational period (38.2 weeks) and 
average birth weight (3295g) of deliveries from blastocyst thaw cycles across Australia 
and New Zealand in 2016 were shorter and lighter respectively than the parameters 
from this present study. However, the average maternal age in Australia and New 
Zealand was almost 2 years older (35.4 years). The similar average gestation and birth 
weight to the Australian population contradicts some previous reports that birth weights 
from ART cycles are lower (Hansen et al., 2009; Z. Li, Wang, Ledger, & Sullivan, 2014). 
This could possibly be explained as mothers utilising ART are less likely to have smoked 
and more likely to be first time mothers (Fitzgerald et al., 2018). Interestingly, the sex 
ratio of babies from this present study was 100 males for every 100 females compared 
to 109 for ART in Australia and New Zealand and 106 for all Australian births in Australia 
in 2016 (Australian Institute of Health and Welfare, 2018; Fitzgerald et al., 2018). 
Blastocyst culture and cryopreservation have been implicated in reports of adverse 
neonatal outcomes, however the findings of preterm birth for blastocyst culture and 
large birthweight for cryopreserved blastocysts were not replicated in the study 
population of this present study (Maheshwari, Kalampokas, Davidson, & Bhattacharya, 
2013; Maheshwari, Raja, & Bhattacharya, 2016). There is significant variance in the 
reporting of adverse outcomes between clinics and regions and large meta-analyses 
cannot capture the various protocol differences. It has been well described in a review 
that different culture conditions can adversely influence embryo metabolism and 
subsequent extended culture outcomes (Wale & Gardner, 2015). It is not clear as to the 
embryo culture conditions of the units contributing data to the study by Maheshwari et 
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al, (2013). A survey of similar units however, revealed the majority were using 
atmospheric oxygen (20%) as opposed to reduced oxygen tension (5-6%) during embryo 
culture (Christianson et al., 2014). The use of atmospheric oxygen for embryo culture 
ignores the negative effects identified in many mammalian species including humans 
(Gardner, 2016). Blastocyst culture in this present study was consistently with a low 
oxygen tension of 6.0% with occasional embryo handling at atmospheric oxygen levels. 
This could possibly explain the relatively normal singleton outcomes after blastocyst 
culture and cryopreservation compared to those reporting for the Maheshwari et al 
2013 and 2016 meta-analyses.  
5.3.3 Maternal Age 
It is generally accepted that the human oocyte arrests at the prophase stage of the first 
meiotic division between the fourth and sixth months of life in utero (Johnson, 2018). 
Despite claims of potential postnatal oogenesis (Johnson, Canning, Kaneko, Pru, & Tilly, 
2004), there remains little consensus on the existence of stem cells in the adult ovary 
(Sophie, Céline, Marina, Sylvie, & Célia, 2019). So, unlike most somatic cells, oogonia are 
potentially immortal until recruited by folliculogenesis that occurs every day from before 
birth to menopause (Gougeon, 1996). Unfortunately, this finite population of ovarian 
follicles and senescence over time appears irreversible and is the primary cause of 
ovarian aging and reduced fecundity with age (Kirkwood, 1998).   Even ART cannot 
compensate for the 30-50% drop in fecundity caused by delaying attempts to conceive 
until a maternal age >35 years (Templeton, Morris, & Parslow, 1996; Wang et al., 2017). 
The most significant predictor of the outcome after a warmed blastocyst transfer in this 
present study was maternal age at the time of vitrification. Results showed those 
patients ≤ 38 years were more than twice as likely to achieve a live birth than those > 38 
years after controlling for the cycle type and transfer attempt. The patients in this 
present study had already generated quality blastocysts in a fresh cycle for 
cryopreservation but maternal age still has an influence on the aneuploidy of blastocysts 
despite good morphology (Cimadomo et al., 2014). 
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5.3.4  Embryo Transfer Cycle 
5.3.4.1 Endometrial preparation and timing of embryo transfer  
Sufficient hormonal preparation of the endometrium is essential to provide an adequate 
environment for the developing embryo. Successful implantation requires both 
endometrial receptivity and synchronicity between both the embryo and the 
endometrium (Devroey & Pados, 1998).  
5.3.4.1.1 Modified natural cycles  
In patients who have regular cycles, it is possible to prepare the endometrium with the 
endogenous hormones produced by the naturally developing follicle. This requires 
thorough monitoring of LH levels and endometrium thickness to ensure the accurate 
timing of ovulation and subsequent transfer (Casper & Yanushpolsky, 2016). Although 
sometimes described as a simpler form of endometrial preparation, it can require 
frequent clinic visits with less cycle control and more cancellations (Sathanandan et al., 
1991). An LH rise signifies ovulation in the following 36 to 40 hours (Andersen, Als-
Nielsen, Hornnes, & Franch Andersen, 1995) although definitions of an LH rise vary 
between centres (Mackens et al., 2017). To avoid asynchrony that could result from a 
missed LH surge, modified natural cycles use an exogenous trigger of ovulation when a 
follicle reaches 16mm or greater in size. A reduced proportion of modified NAT cycles 
(12.3%) were used in this present study as it required frequent clinic visits and a 
significant number of patients were based in rural areas. Despite this difficulty, the 
outcomes from these cycles were significantly better than those managed by HRT. Of 
the 283 embryos transferred in modified NAT cycles, 105 (37.1%) babies were born. This 
is significantly greater than the 25.4% (280/1103) from HRT cycles (Table 4-4). Using 
multiple regression controlling for age and transfer rank, non HRT cycles are almost 38% 
more successful at producing a live born baby compared to the HRT cycles (Table 4-9). 
Despite individual studies demonstrating a similar conclusion (Alama et al., 2007; Chang 
et al., 2011; Xiao, Zhou, Xu, Yang, & Xie, 2012), repeated reviews in the literature, 
however have found no evidence that favours one cycle type over another 
(Groenewoud, Cantineau, Kollen, Macklon, & Cohlen, 2013; Groenewoud, Cohlen, & 
Macklon, 2018). 
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5.3.4.1.2 Low dose ovarian stimulation cycles 
The use of gonadotrophins to control a cycle for the transfer of a frozen-thawed embryo 
has diminished after repeated studies showed no difference to natural, modified natural 
and HRT cycles (Ghobara & Vandekerckhove, 2008). Recent meta-analyses have not 
even included gonadotrophin stimulated cycles as part of the analysis (Groenewoud, 
Cantineau, Kollen, Macklon, & Cohlen, 2017; Mackens et al., 2017). In this present study 
however, 40% of cycles were prepared by a low dose gonadotrophin stimulation 
protocol. Clinical review within the unit concluded that the added cycle control 
alleviated problems with timing of ovulation and subsequent FET that are afforded to 
natural cycle management. Older patients also benefited from augmentation of 
spontaneous endometrial enrichment during the follicular phase. There was no 
significant difference between the 32.3% live birth rate of LDS cycles compared to the 
37.1% success rate of modified natural cycles in this present study. 
5.3.4.1.3 Hormone Replacement Cycles 
Most of the cycles in this present study were prepared with the use of sequentially 
delivered exogenous oestrogen and progesterone supplementation (47.7%). One of the 
greatest benefits of the hormonally controlled cycle is that the proliferative phase can 
be adjusted without compromising the implantation window (Simon et al., 1999; Soares 
et al., 2005). This is convenient for programming cycles and suitable for those 
anovulatory patients and those with irregular cycles. Unlike the consensus in the 
literature (Groenewoud et al., 2018), the outcomes from HRT cycles in this present study 
were significantly (p<.0001) poorer than those cycles prepared by natural means or 
supplemented with gonadotrophins (25.4% vs 32.3% and 37.1%). There is little 
agreement regarding the timing of embryo transfer for HRT cycles (Nawroth & Ludwig, 
2005) but a Cochrane review concluded that starting progesterone supplementation on 
the day equivalent to the day of egg collection or the day after resulted in greater 
success than commencing progesterone a day before the theoretical day of egg 
collection (Glujovsky et al., 2010). In this present study both D5 and D6 blastocysts were 
transferred on the 6th day of progesterone supplementation. This timing is considered 
too late by some authors and therefore a trial of transfer on the 5th day could be 
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considered (Escriba et al., 2006; Glujovsky et al., 2010; Mackens et al., 2017; van de 
Vijver et al., 2017). 
5.3.4.2 Embryo transfer rank 
In chapter 9 of the 2018 NPESU report, data is presented from an ongoing longitudinal 
study of patients commencing autologous treatment at the start of 2014, following their 
progress up to the end of 2016 (Fitzgerald et al., 2018). This provides an indicator of the 
pathway of treatment a patient takes if they are unsuccessful with their first embryo 
transfer. It excludes freeze-all cycles and patients drop out of the study when they have 
a successful delivery. Subsequent cycles maybe frozen or fresh transfers. The data shows 
a significantly reducing success rate as the transfer rank increases. In this present study 
there is also a significant reduction in success rates with subsequent embryo transfers. A 
direct comparison cannot be made as the NPESU data excludes subsequent cycles after 
a delivery and it is per cycle data rather than the per transfer data of this present study. 
However, the downward trend still exists in both data sets. In this present study more 
than 50% of embryo transfers were of the order of 3 or greater and the live delivery rate 
of 1st embryo transfers (38.7%) was significantly greater than the 26.5% and 20.8% of 
the 3-5 and 6-20 transfer rank groups (Table 4-6). Before the use of blastocyst culture 
became prevalent, studies showed that repeated cycles had similar success rates 
(Meldrum, Silverberg, Bustillo, & Stokes, 1998). This was however disputed for those 
that attained a pregnancy and were returning for another (Molloy, Doody, & Breen, 
1995). Shapiro et al. (2001) reported contradicting significant declines in success rates 
for repeated cycles and suggested an explanation of improved culture techniques and 
blastocyst transfer. They showed an implantation rate of 30% for 1st transfers, 18% for 
2nd transfers and 8% for 3rd (Shapiro, 2001). In this present study the equivalent 
implantation rate was 41.8%, 32.9% and 30.0% respectively. The reduced decline in 
comparison can be explained as this data set is for a period of 8 years and allows for 
patients returning after pregnancy to be included in the study.  It is also only for vitrified 
blastocysts that come from cycles with improved outcomes (Wang et al., 2008). Vitrified 
blastocyst outcomes also benefit from the inclusion of freeze all patients that have been 
shown to have an increased proportion of patients that are good responders after 
ovarian stimulation (Tarlatzis, Grimbizis, Bosdou, Kolibianakis, & Venetis, 2019). In a 
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recent multicentre, non-blinded, randomised controlled trial in 21 academic fertility 
centres in China it was demonstrated that there was a 26% improvement in the freeze 
all singleton live birth rate compared to fresh cycles (Wei et al., 2019). 
 
5.4 Blastocyst Morphology and Development Rate 
5.4.1 Day 5/6 
Development rate has been the most prevalent of embryo assessment criteria (Cummins 
et al., 1986; Hossain et al., 2016). This criterion holds for both the cleavage stage 
embryo and the blastocyst stage (Shapiro, Richter, Harris, & Daneshmand, 2001). In this 
present study, blastocysts were selected for vitrification either on day 5 or day 6 of 
development after insemination (Day 0). Controlling for morphology and the degree of 
expansion, day 5 blastocysts had an 80% greater chance of resulting in a live birth 
compared to day 6 blastocysts. Previous comparisons of fresh day 5 vs day 6 transfers 
have shown a similar or greater difference in success rates (Barrenetxea et al., 2005; 
Dessolle et al., 2011; Schoolcraft et al., 1999b; Shapiro et al., 2001). These studies relied 
on non-elective selection of the day 6 blastocyst transferred and therefore represented 
developmentally delayed blastocysts that did not meet the requirements of selection on 
Day 5. A subsequent study comparing elective Day 6 transfers showed the odds ratio of 
day 6 transfers to be 0.34 (Poulsen, Ingerslev, & Kirkegaard, 2017). They suggested the 
difference was likely to be the detrimental effects of prolonged culture or asynchrony 
with the endometrium in a fresh cycle. Some studies on replacement of frozen day 5/6 
blastocysts in subsequent controlled cycles have shown little difference when blastocyst 
quality is similar (Richter, Shipley, McVearry, Tucker, & Widra, 2006; Sunkara et al., 
2010). Sunkara et al., (2010) in a meta-analysis of studies comparing day 5 and 6 
blastocysts concluded that if the morphology grade was controlled day 5/6 outcomes 
were comparable in subsequent programmed frozen cycles.  They speculated that the 
endometrial-embryonic synchronisation could be more important than the blastocyst 
development rate in contributing to treatment outcome. This present study however 
contradicts these findings after controlling for blastocyst grade (OR 1.64) and expansion 
(OR 2.01). More recent studies comparing Day 5/6 outcomes from vitrified/warmed 
blastocysts also confirm that despite good quality blastocysts on Day 6 they do not 
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achieve the same outcomes as blastocysts vitrified on Day 5 (Ferreux et al., 2018b; Haas 
et al., 2016). However this does not fully remove the possibility of the differently primed 
endometrium playing a role in the implantation potential of the blastocyst (Weimar et 
al., 2012). Berrin et al (2018) also vitrified blastocysts developing on Day 7 and found 
similar implantation rates between Day 6 and 7 blastocysts (Berrin et al., 2018). 
5.4.2 Pre-vitrification Expansion and Morphology  
The assessment of blastocysts for vitrification used a combined ICM and trophectoderm 
score (Roy, Bradley, et al., 2014). Expansion level assessment is an indicator of embryo 
competence as it requires significant energy for sodium/potassium ATPases and the 
multi-protein tight junctions between trophectoderm cells to form a barrier (Alpha 
Scientists in Reproductive Medicine, 2011; Gardner & Schoolcraft, 1999a, 1999b). This 
criterion was first designed to be used as a rapid assessment tool under a dissecting 
microscope. The morphology grade, however, is easier to allocate at the more expanded 
stages as the visibility of the distinct cell types is clearer using an inverted microscope. 
The results in this present study confirm this by showing no significant influence of 
morphology grade on survival or live birth rate until there was significant expansion in 
the embryo on Day 5 (Table 4-11).  Unexpanded blastocysts with a morphology grade 1 
on day 5 had a greater delivery rate compared to grade 2 (28.0% vs 22.7%) however the 
difference was not significant as very few unexpanded blastocysts were given a 
morphology grade of 1. Similar findings from Ahlstrom et al (2011) showed that 
trophectoderm morphology was the strongest morphology predictor only when there 
was significant expansion in the blastocyst (Ahlstrom et al., 2011). In this present study, 
despite expansion on day 6, the significance of embryo grade is reduced as the 
development stage becomes the most significant indicator of viability. The ranking of 
embryos by combining survival and live birth outcomes in the present study confirms 
the importance of development rate (day 5/6) and the expansion level/morphology 
grade on day 5 and provides a useful tool for managing patient expectations and 
prioritising embryos for warming and transfer. 
5.5 Vitrification Technique 
The cooling/warming rates are critical criteria affecting blastocyst survival after 
vitrification in addition to the cryoprotectant concentrations, exposure time and 
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temperature (Kader, Choi, Orief, & Agarwal, 2009). Although there was no significant 
difference in live birth rates between techniques in this present study, the survival rate 
determines the embryos that make it to transfer for that calculation. This is an 
important factor often missed when looking at meta analyses suggesting the benefits of 
freeze all policies (Wei et al., 2019). 
5.5.1 Vitrification Device  
Although the cooling/warming rates using the FibreplugTM are unpublished it is assumed 
to be slower than the Cryotop® device as the volume of the sample is 20 to 30 times 
greater and the cooling/warming rates are inversely proportional to volume and risk of 
ice crystallisation (Vanderzwalmen et al., 2002). The reduced cooling/warming rates of 
the FibreplugTM in this present study could be an explanation of the lower blastocyst 
survival compared to the Cryotop (83.9% vs 91.2%). When vitrification of mouse 
embryos was first achieved in 1985, they were limited by cooling and warming rates 
<3000°C/min using a 45 µl drop drawn into a 0.25 ml plastic straw (Rall & Fahy, 1985). 
They manipulated the warming rate while keeping the cooling rate consistent and found 
significant differences in survival rates from 0% to 87.8%. Although there was success 
with the use of these straws for human blastocysts (Yokota, Sato, Yokota, Yokota, & 
Araki, 2001) the first birth from vitrified human blastocysts came from a group in Seoul, 
Korea using an electron microscope (EM) copper grid (Choi et al., 2000). The 26 µm bar 
diameter and 38 µm pore size of the 3mm diameter EM grid allowed direct exposure to 
liquid nitrogen with a more rapid cooling rate. The grid was subsequently inserted into a 
cryo vial pre-filled with liquid nitrogen and mounted on a cryo cane for storage. The 
survival rate of 51.6% was most likely more related to the use of EG as a single CPA 
rather than slower cooling/warming rates. Other devices also focussing on a reduced 
volume of the sample to be vitrified include the open pulled straw (OPS) and the 
cryoloop (Lane et al., 1999; Mukaida et al., 2003; Reed et al., 2002; G. Vajta, Holm, 
Greve, & Callesen, 1997). Despite the success of these devices, the rapid cooling rate 
(>20,000°C) and rapid warming rate (>40,000°C) of the Cryotop® due to the very small 
volumes (< 1µl) needed to contain the embryo have not been surpassed for clinical use 
on human embryos (Kuwayama, Vajta, Kato, et al., 2005). All these methods do however 
utilise direct exposure to liquid nitrogen to enhance their cooling and warming rates. 
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Due to concerns over contamination (Bielanski, Bergeron, Lau, & Devenish, 2003) from 
liquid nitrogen the development of closed systems have been explored (Papatheodorou 
et al., 2013). Both devices used during this present study were open systems with 
exposure to liquid nitrogen in the storage phase but utilised a sterilised vitrification 
block to vitrify the blastocysts prior to storage. The manufacturers of both devices have 
subsequently offered closed alternatives (Huang, 2016; Gábor Vajta, Rienzi, & Ubaldi, 
2015).  
In addition to the difference in shape between the two carrier devices there were also 
variations in the associated protocols that could explain an improved survival rate with 
the Cryotop device (Table 5-1). The equilibration time was significantly shorter with the 
Fibreplug (2 min vs 15 min) and temperature was 37 degrees Celsius compared to 19-23 
degrees Celsius with the Cryotop. Due to multiple variances it is difficult to determine 
which of them would influence survival more than the other. A conclusion on blastocyst 
survival cannot therefore be attributed to the device only and it is important to further 
analyse differences in the pre-handling of the blastocyst (artificial collapsing) and the 
vitrification/warming media used. 
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 Table 5-1 Cryotop® and FibreplugTM Methods 
 FibreplugTM Cryotop® 
Equilibration temp 37°C 19-23°C 
Equilibration time 2 min 15 min 
Artificial collapsing YES NO 
Visualisation NO YES 
SSV YES YES 
Cooling rate Unpublished 22,800°C/min (Kuwayama, Vajta, Kato, et al., 2005) 
Warming rate Unpublished 42,100°C/min (Kuwayama, Vajta, Kato, et al., 2005) 
Vitrification volume 3 µl <0.1 µl 
Warming temp 37°C 37°C 
Re-equilibration temp 37°C 19-23°C 
 
5.5.2 Blastocyst Collapsing 
In the FibreplugTM group of this present study the reduction of the blastocoel was 
performed by manual pipetting of the blastocyst through a reduced diameter pipette 
prior to exposure to the final vitrification solution. Previous studies had shown that 
blastocyst survival rates were reduced due to the expanded blastocoel not completely 
being devoid of water and replaced with CPA, increasing the risk of ice crystal damage.  
Blastocoel reduction by micro-needle aspiration, laser, hyperosmotic pressure (sucrose) 
and the manual pipetting were performed (T. Ebner & Shebl, 2018; Hiraoka, Hiraoka, 
Kinutani, & Kinutani, 2004; Kovačič, Taborin, & Vlaisavljević, 2018; Son, Yoon, Yoon, Lee, 
& Lim, 2003; Vanderzwalmen et al., 2002). In a study with mouse blastocysts, Frank et al 
(2019) concluded that the Na+/K+-ATPase driven water transport mechanisms were 
responsible for the majority of the re-expansion process after vitrification and warming 
72 
 
(Frank et al., 2019). They explained that a decreased cell survival due to not performing 
artificial collapsing prior to vitrification lead to these mechanisms being compromised 
and having to rely on passive mechanisms as measured through aquaporin transcripts 
Aqp3 and 8. They suggested this to be the mechanism resulting in artificially collapsed 
blastocysts re-expanding faster than those that were not artificially collapsed, however 
their study utilised laser collapsing as opposed to the manual pipetting method used in 
this present study. Their finding conflicts with the assessment in this present study that 
blastocysts vitrified on the Cryotop® device, that were not pre-treated with artificial 
collapsing, re-expanded quicker than those blastocysts vitrified on the FibreplugTM 
(Figure 4-6). Artificial collapsing was not performed in the Cryotop® group as the 
blastocoel collapses and partially re-expands spontaneously during the first equilibration 
phase of the vitrification process. Equivalent success compared to fresh blastocyst 
transfer has been published using this method (Roy, Bradley, et al., 2014) but some 
groups still routinely perform this pre-treatment prior to vitrification with the Cryotop® 
(Du et al., 2016). As part of a study on aseptic vitrification, Vanderzwalmen et al (2009) 
concluded that the longer equilibration using lower concentrations of cryoprotectants at 
room temperature allowed sufficient cryoprotectant to enter the blastocoel to avoid ice 
crystal formation (Vanderzwalmen et al., 2009). A prospective RCT investigating the 
effect of artificial shrinkage (collapse) on the implantation potential of vitrified 
blastocysts found the artificial shrinkage by laser-induced collapse did not significantly 
increase the implantation rate per transferred collapsed blastocyst compared with non-
collapsed blastocysts, however there was a significant improvement in survival rate (Van 
Landuyt et al., 2015). Although there is no evidence artificial blastocoel collapse can 
negatively affect survival and implantation outcomes, it was concluded for the protocols 
using Cryotop® in this present study that the procedure was an added handling risk and 
unnecessary. The extended equilibration time in the Cryotop protocol allows for gradual 
blastocoel collapse due to the removal of water and re-expansion as the blastocoel fluid 
is replaced with cryoprotectants. 
5.5.3 Vitrification/Warming Media 
The successful formula for vitrification media for human oocytes and embryos has 
remained consistent for the past decade with most formulations consisting of EG and 
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DMSO in equal proportions along with a carbohydrate acting as an osmotic buffer 
(Argyle et al., 2016). Each cryoprotectant has a role to ensure the formation of a 
solidified amorphous liquid state of high viscosity at a low temperature that spans both 
the intra and extra-cellular space (Fuller & Paynter, 2004). The concentrations of the 
permeable low molecular weight cryoprotectants used in this present study are the 
result of many years of trials with animal and human embryos (Leibo & Pool, 2011). They 
are similar for both sources of vitrification media used in this present study (8-16% v/v 
DMSO, 8-16% v/v EG) and are used with similar concentrations in many other centres 
worldwide (Table 5-2). Although the concentrations are similar, the temperature and 
duration of exposure differs between the two vitrification methods in this present study 
(Table 5-1).  Permeability coefficients and associated activation energies of water and 
various CPA’s differ with the changing surface area to volume ratio from the oocyte 
through to the blastocyst (Pedro et al., 2005).   Jin et al (2013) showed in the pig 
blastocyst that the activation energy for permeability to water, glycerol, DMSO, and EG 
was markedly lower for blastocysts compared to oocytes (Jin et al., 2013). The exposure 
to CPA’s at 37°C in the Fibreplug protocol of this present study, although for a short 
period, could explain the difference in survival rates between the two techniques 
considering the CPA concentrations were identical.   
Although the blastocyst survival rate was significantly greater with the Cryotop device in 
the present study, this difference was not maintained when controlling for the media 
type used during warming. This suggests a possible influence on blastocyst survival due 
to the composition of the warming media. Carbohydrates such as sucrose and trehalose 
are also used to supplement the handling media during warming. The increased solute 
concentration provided by the carbohydrate reduces the osmotic gradient across the 
cell membrane as the cryoprotectant permeates to the extracellular space (Dinnyés, Dai, 
Jiang, & Yang, 2000). In this present study, warming solutions with different 
formulations from 3 different suppliers were used.  Carbohydrate levels as high as 1 M 
were used to reduce the speed and magnitude of cellular swelling in the blastocyst 
(Liebermann, Dietl, Vanderzwalmen, & Tucker, 2003). It is thought that the higher 
osmotic buffer level compensates for the increased permeability of CPA’s through 
aquaporin water channels in the blastocyst (Pedro et al., 2005). Initially single step 
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carbohydrate dilutions were used during warming but multiple step reductions were 
shown to improve outcomes (Cho, Son, Yoon, Lee, & Lim, 2002). Early studies on mouse 
zygotes show significant changes in survival to blastocyst after EG exposure based on the 
use of differing levels of sucrose (Oda, Gibbons, & Leibo, 1992). Results for both 
vitrification devices in this present study favour the use of lower concentrations of 
osmotic buffer, however it is difficult to determine whether the effect is coming from 
the carbohydrate or other additions to the media.  
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 Table 5-2 Published Blastocyst Vitrification Methods 
Reference Collapse CPA Time Temp Device Warming 
Media 
Time Temp Culture Survival 
(Zhao, Yan, 
Huang, Sun, 
& Li, 2019) 
Yes 
Laser 
7.5% EG/DMSO 
15% EG/DMSO 
0.5M Sucrose 
8-10 min 
1 min 
Not 
stated 
Cryoloop 1 M Sucrose 
0.5 M 
0 M 
2 min 
3 min 
10 min 
RT 
RT 
37°C 
3 hrs Not stated 
(Berrin et 
al., 2018) 
Yes 
Laser 
7.5% EG/DMSO 
15% EG/DMSO 
0.5M Sucrose 
6-10 min 
80-110 s 
RT Cryoleaf 1 M Sucrose 
0.5 M 
0 M 
1 min 
4 min 
8 min 
37°C 
RT 
RT 
4 hrs Not stated 
(Kovačič et 
al., 2018) 
Yes vs No 7.5% EG/DMSO 
15% EG/DMSO 
0.5M Sucrose 
10 min 
1 min 
RT HSV 
Spatula 
1 M Sucrose 
0.5 M 
0 M 
1 min 
4 min 
8 min 
37°C 
RT 
RT 
>140 
min 
97.2-100% 
(Cimadomo 
et al., 2018) 
Yes 7.5% EG/DMSO 
15% EG/DMSO 
0.5% Sucrose 
14 min 
1 min 
RT Cryolock 1 M Sucrose 
0.5 M 
0 M  
1 min 
3 min 
5 min 
37°C 
RT 
RT 
>120 
min 
99% 
(Ferreux et 
al., 2018b) 
Yes vs No 7.5% EG/DMSO 
15% EG/DMSO 
0.5% Sucrose 
14 min 
Not 
stated 
RT CBS-Vit-HS 1 M Sucrose 
0.5 M 
0 M 
3 min 
4 min 
3 min 
37°C 
RT 
RT 
120-240 
min 
95% 
(Coello et 
al., 2017) 
No 7.5% EG/DMSO 
15% EG/DMSO 
0.5% Sucrose 
12 min 
1 min 
RT Cryotop 1 M Sucrose 
0.5 M 
0 M 
1 min 
3 min 
6 min 
37°C 
RT 
RT 
120 min 97.2% 
(Ebner et 
al., 2017) 
No 10% EG/DMSO 
20% EG/DMSO 
0.5% Sucrose 
1-3 min 
1 min 
RT Cryotop 0.5 M 
Sucrose 
0.25 M 
0.125 M 
0 M 
3 min 
 
2 min 
2 min 
1 min 
37°C 
RT 
RT 
RT 
RT 
Average 
4.5 hrs 
87.8% 
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5.6 Embryo assessment post warming 
The estimation of the proportion of cell degeneration in a collapsed blastocyst after 
warming is difficult and the methodology is not described well in the literature (Edgar & 
Gook, 2012). Despite this paucity in methodology, early reports used the survival criteria 
also used for cleavage stage embryos that at least 50% of the trophectoderm and ICM 
must have survived to proceed to transfer (Behr, Gebhardt, Lyon, & Milki, 2002).  In this 
present study it was found that the commencement of re-expansion within 60 minutes 
of the warm was a more reliable indicator of survival than the estimation of cell 
degeneration and was used as the sole survival criterion for most of the study. This 
requirement persisted regardless of the size of the cavity prior to vitrification. Re-
expansion has been identified as important in recent studies but this present study is the 
first describing the time to commencement of re-expansion as the sole determinant of 
blastocyst survival (Coello et al., 2017; Ebner et al., 2017; Ferreux et al., 2018a; Marren 
et al., 2016). Kovačič et al., (2018) included this criterion along with at least 50% cell 
survival (Kovačič et al., 2018) when assessing blastocysts after warming. The 
classification of a warmed blastocyst as survived may vary in different laboratories and 
in the literature (Edgar & Gook, 2012). These variations are due to assessments being 
done at different times according to different protocols (Ebner et al., 2009). It is possible 
also that if embryologists are put under a time pressure scenario there may not be 
enough time available to warm further blastocysts and this could bias the survival 
assessment (Alpha Scientists in Reproductive Medicine, 2012). For this reason, it is 
preferable for an IVF unit to be flexible as to when a warmed blastocyst can be 
transferred to ensure the best outcome for the patient. Some authors recommend 
warming 24 hrs prior for this reason, however a significant negative effect of day 6 
blastocysts would make this difficult to justify (Sunkara et al., 2010; Vanderzwalmen et 
al., 2003). The Alpha Consensus on Cryopreservation does not allow for re-expansion 
assessment; however, it does include a transfer rate KPI in addition to a survival KPI 
(Alpha Scientists in Reproductive Medicine, 2012). This present study did not find any 
detrimental effects from the length of time between the warm and the transfer, when 
the transfer was performed on the same day as the warm. 
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Of the blastocysts deemed to have survived in this present study, records were kept of 
the proportion of degenerated cells and whether they commenced re-expansion within 
30 or 60 minutes. It is difficult to obtain consistency amongst embryologists in 
estimating the proportion of degenerated cells so any estimations of 100% survival were 
combined with those of 95% and these compared with 70 to 94% assessments. A simple 
comparison of 30 min and 60 min commencement of re-expansion showed a 
significantly improved delivery rate of blastocysts commencing re-expansion within 30 
minutes. This difference however became insignificant when controlling for the 
proportion of cell degeneration. 
5.7  Summary 
5.7.1 Findings 
Double embryo transfers, despite strict criteria for inclusion, still produced unacceptable 
multiple pregnancy rates in this present study. Singleton deliveries from SET’s of a 
vitrified/warmed blastocyst have a similar gestational age and weight at birth to the 
Australian population whether ART was used or not. The sex ratio (M: F) of these babies 
in the present study was 100:100 compared to 109:100 of ART births in Australia and 
New Zealand in 2016 and 106:100 in the Australian population of all births. 
Maternal age is the strongest predictor of birth outcome and developmental age of the 
blastocyst post insemination remains the strongest embryo specific variable to influence 
outcome, even when all blastocysts were replaced on Day 5 in a controlled cycle. 
Blastocyst morphology grade does not influence the live birth rate unless the blastocyst 
is at the expanded stage or greater. 
Survival rates are improved when the vitrification volume is reduced, no artificial 
collapsing is performed and a longer equilibration period at room temperature is used. 
Osmotic buffer levels in warming media may contribute to blastocyst survival rate. The 
commencement of blastocyst re-expansion is a good indicator of blastocyst survival at 
60 minutes and easier to measure than the proportion of cell degeneration. Evidence of 
cell degeneration greater than 5 % significantly affects the live birth rate. 
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5.7.2 Implications 
Current double embryo transfer decisions need refining to reduce the multiple 
pregnancy rate for those procedures in this present study. The similar gestational period 
and birth weight compared to all singleton births contradicts reports of different 
outcomes for the ART population. Patients should be fully informed of the poorer 
outcomes from blastocysts utilised on Day 6 whether in a controlled fresh or frozen 
cycle. Blastocyst grading of ICM and trophectoderm cells should be reserved for 
blastocysts that are expanded or greater. Patients are best informed of the proportion 
of degenerative cells to be able to decide if they wish to improve their chances of a live 
birth by warming another embryo. If an embryologist has doubt about the proportion of 
degenerative cells in the warmed blastocyst then the early commencement of re-
expansion is a quick confirmation within one hour of the warm. 
5.7.3 Limitations 
This present study was retrospective, so unknown residual confounding factors could be 
influencing the results and subsequent findings. The study period was extensive and 
there may be uncontrolled variables from changes in protocols, including blastocyst 
grading expertise over time. These could be clinical, or laboratory related. Morphology 
grading in this study was a combined ICM and trophectoderm score and therefore a 
grade 2 blastocyst may contain a grade 1 ICM or trophectoderm. The conclusions made 
in this study reflect the protocols used in one IVF unit and may not be able to be 
extrapolated to other units. This study targets vitrified/warmed blastocysts of a good 
grade only and therefore findings are restricted to this embryo population only. Due to 
the difficulty in cell degeneration assessment there may be some inter-operator 
variability in embryo assessment post warm.  The data in this study is at the embryo 
level and therefore a single patient may be in the data set more than once and patient 
specific factors may influence the results. Day 6 development age blastocysts are used 
for transfer only when the supply of suitable day 5 blastocysts is exhausted. This may 
negatively influence conclusions about transfers with Day 6 embryos. All neonatal 
outcomes in this study were obtained from patient questionnaires rather than medically 
validated birth reports and may influence the birth outcome records.  
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5.7.4 Future Research 
Better criteria for double embryo transfer should be explored to reduce multiple birth 
rates or have the practice eliminated. Adjustments and comparisons of the different 
replacement cycle control methods could further improve synchronisation of the 
endometrium to the blastocyst. Controlled comparisons of warming solutions with 
different concentrations/type of carbohydrate osmotic buffer but same base media 
should be performed as there are a wide range of concentrations currently in use in 
clinical practice. The feasibility of altering the logistics of blastocyst thaw and transfer 
timing should be explored to allow for sufficient time for embryo assessment prior to 
transfer. The use of more recent data using cell specific grading, time-lapse culture and 
automated vitrification could validate the conclusions in this study. D5/6 vitrification and 
transfer decisions could be validated by more accurate timings obtained from time lapse 
data. 
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7.2 Data Field Table 
Table 7-1 Data Fields Retrieved from Hollywood database 
Field Name Definition Format Content 
Patient Identification code Unique 
patient 
identification 
code used for 
de-identifying 
purposes 
Numerical 5 figure 
number 
Aetiology Underlying 
cause of 
infertility 
Nominal  Male factors 
only, Multiple 
causes, Other 
female only, 
Tubal only, 
Unexplained 
Fertilisation code Single number 
representing 
unique 
fertilisation 
event 
Numerical 1-4 
Transfer code Single number 
representing 
unique 
transfer event 
Numerical 1-7 
Age at time of Cryopreservation Maternal age 
at the time 
the embryo 
was vitrified 
Numerical Age in years 
104 
 
Date of Cryopreservation Date of 
Vitrification 
Date  dd/mm/yyyy 
Straw Number Unique 
embryo 
identifier 
Numerical 
(2 part 
with year 
and 
number) 
yy/0001 
Blast Stage Stage of 
blastocyst at 
time of 
vitrification 
Nominal EB,B,XB,HB,FHB 
Day 5/6 Day of 
vitrification 
Numerical 5/6 
ICM ICM Grade Numerical 1-2 
TE TE Grade Numerical 1-2 
Blast Blastocyst 
Grade 
Numerical 1-2 
Date of Warm Date of Warm Date dd/mm/yyyy 
Time of Warm Time of Warm Time hh:mm 
Exp Time till 
expansion 
commences 
Time 
(minutes) 
mmm 
Survival Proportion of 
cells survived 
Numerical 
(%) 
%% 
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Fate Whether 
Transferred or 
Discarded 
Nominal R or D 
Date of Transfer Date of 
Embryo 
Transfer 
Date dd/mm/yyyy 
Time of Transfer Time of 
embryo 
transfer 
Time hh:mm 
#ET Number of 
embryos 
transferred 
Numerical 1-3 
Cycle Type of 
replacement 
cycle  
Nominal LDS,NAT,HRT 
qhCG Quantitative 
hCG level at 
pregnancy 
test 
Numerical Nnn (IU) 
SACS Number of 
sacs on US 
Numerical  
FH Number of 
heart beats on 
ultrasound 
Numerical  
LMP Date of last 
menstrual 
Date dd/mm/yyyy 
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period (start 
of cycle) 
DOB Date of Birth Date dd/mm/yyyy 
1SEX Sex of Baby1 Nominal Male or Female 
1BW Weight of 
Baby1 
Numerical grams 
1BIRTH Mortality of 
Baby1 
Nominal Live or Still 
1GEN Any genetic 
malformations 
of Baby1? 
Nominal Yes or No 
2SEX Sex of Baby2 Nominal Male or Female 
2BW Weight of 
Baby2 
Numerical grams 
2BIRTH Mortality of 
Baby2 
Nominal Live or Still 
2GEN Any genetic 
malformations 
of Baby2? 
Nominal Yes or No 
3BW Sex of Baby3 Nominal Male or Female 
3SEX Weight of 
Baby3 
Numerical grams 
3BIRTH Mortality of 
Baby3 
Nominal Live or Still 
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3GEN Any genetic 
malformations 
of Baby3? 
Nominal Yes or No 
 
7.3 Product Inserts and Detailed Protocols 
 
Appendix 7.3 is not available in this version of the thesis. 
